0001437749-24-011541 | 10-Q | XBRL Viewer

Noncontrolling Interest Disclosure [Text Block]

Note 17. Non-controlling interests

The following tables summarize the information relating to the Company’s subsidiaries, SH Acquisition (68%), CC Pharma Nordic ApS (75%), Aphria Diamond (51%), and ColCanna S.A.S. (90%) before intercompany eliminations.

Summary of balance sheet information of the entities in which there is a non-controlling interest as of February 29, 2024:

	SH		*CC Pharma*			*Aphria*			*ColCanna*			*February 29,*
	*Acquisition*		*Nordic ApS*			*Diamond*			*S.A.S.*			*2024*
Current assets	$	—	$	31		$	81,541		$	191		$	81,763
Non-current assets		32,000		—			129,067			3,719			164,786
Current liabilities		—		(14	)		(129,422	)		(6,786	)		(136,222	)
Non-current liabilities		—		—			(48,218	)		(1,458	)		(49,676	)
Net assets	$	32,000	$	17		$	32,968		$	(4,334	)	$	60,651

Summary of balance sheet information of the entities there is a non-controlling interest as of May 31, 2023:

	SH		*CC Pharma*			*Aphria*			*ColCanna*			*May 31,*
	*Acquisition*		*Nordic ApS*			*Diamond*			*S.A.S.*			*2023*
Current assets	$	—	$	114		$	127,689		$	224		$	128,027
Non-current assets		74,681		—			135,085			3,307			213,073
Current liabilities		—		(1,166	)		(142,554	)		(6,697	)		(150,417	)
Non-current liabilities		—		—			(53,197	)		(1,428	)		(54,625	)
Net assets	$	74,681	$	(1,052	)	$	67,023		$	(4,594	)	$	136,058

Summary of income statement information of the entities in which there is a non-controlling interest for the nine months ended February 29, 2024:

	SH			*CC Pharma*			*Aphria*			*ColCanna*			*February 29,*
	*Acquisition*			*Nordic ApS*			*Diamond*			*S.A.S.*			*2024*
Revenue	$	—		$	—		$	76,541		$	—		$	76,541
Total expenses		42,681			(1,078	)		47,541			(594	)		88,550
Net (loss) income		(42,681	)		1,078			29,000			594			(12,009	)
Other comprehensive (loss) income		—			(9	)		646			(334	)		303
Net comprehensive (loss) income	$	(42,681	)	$	1,069		$	29,646		$	260		$	(11,706	)
Non-controlling interest %		32	%		25	%		49	%		10	%	NA
Comprehensive (loss) income attributable to NCI		(13,658	)		267			14,527			26			1,162
Additional income attributable to NCI		—			—			5,336			—			5,336
Net comprehensive (loss) income attributable to NCI	$	(13,658	)	$	267		$	19,863		$	26		$	6,498

Summary of income statement information of the entities in which there is a non-controlling interest for the nine months ended February 28, 2023:

	SH			*CC Pharma*			*Aphria*			*ColCanna*			*February 28,*
	*Acquisition*			*Nordic ApS*			*Diamond*			*S.A.S.*			*2023*
Revenue	$	—		$	126		$	98,960		$	—		$	99,086
Total expenses		107,297			659			54,285			91,026			253,267
Net (loss) income		(107,297	)		(533	)		44,675			(91,026	)		(154,181	)
Other comprehensive (loss) income		70,778			(13	)		(707	)		373			70,431
Net comprehensive (loss) income	$	(36,519	)	$	(546	)	$	43,968		$	(90,653	)	$	(83,750	)
Non-controlling interest %		32	%		25	%		49	%		10	%	NA
Comprehensive (loss) income attributable to NCI		(11,686	)		(137	)		21,544			(9,065	)		656
Additional income attributable to NCI		—			—			8,968			—			8,968
Net comprehensive (loss) income attributable to NCI	$	(11,686	)	$	(137	)	$	30,512		$	(9,065	)	$	9,624

On January 5, 2024, Aphria Inc. (“Aphria”), a wholly-owned subsidiary of the Company, entered into an Amended and Restated Wholesale Cannabis Supply Agreement (the “Supply Agreement”) with 1974568 Ontario Limited (“Aphria Diamond”), Aphria’s joint venture with Double Diamond Holdings Ltd. The Supply Agreement amended and restated the existing supply agreement, effective as of September 1, 2023, and amended certain terms relating to pricing and product classes. Due to the terms stipulated in the Supply Agreement, the reduced transfer price will lead to a decrease in income attributable to non-controlling interest over the duration of the agreement. If this agreement had been effective June 1, 2023, the Company would have recognized approximately $15,000 in additional net income attributed to the Stockholders of Tilray Brands, Inc.

Note 11 - Accounts Payable and Accrued Liabilities (Tables)

9 Months Ended

Feb. 29, 2024

Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]

	*February 29,*		*May 31,*
	*2024*		*2023*
Trade payables	$	90,163	$	70,819
Accrued liabilities		70,744		48,394
Litigation accrual		25,153		25,000
Accrued payroll and employment related taxes		14,993		18,772
Income taxes payable		1,438		14,934
Accrued interest		3,202		8,102
Sales taxes payable		4,070		4,661
Total	$	209,763	$	190,682

Note 21 - Cost of Goods Sold

9 Months Ended

Feb. 29, 2024

Cost of Goods Sold [Text Block]

Note 21. Cost of goods sold

Cost of goods sold is comprised of:

	*For the three months ended*				*For the nine months ended*
	*February 29,*		*February 28,*		*February 29,*		*February 28,*
	*2024*		*2023*		*2024*		*2023*
Beverage alcohol costs	$	35,836	$	10,663	$	77,615	$	32,932
Cannabis costs		42,518		80,362		139,507		137,800
Distribution costs		51,231		57,964		172,846		165,443
Wellness costs		9,359		8,299		28,091		26,964
Total	$	138,944	$	157,288	$	418,059	$	363,139

Note 7 - Business Acquisitions - Assets Acquired and Liabilities Assumed (Details) $ in Thousands, $ in Millions	Sep. 29, 2023 USD ($)	Aug. 03, 2023 USD ($)	Aug. 03, 2023 CAD ($)	Jun. 22, 2023 USD ($)	Nov. 07, 2022 USD ($)	Feb. 29, 2024 USD ($)	May 31, 2023 USD ($)
Goodwill						$ 2,009,632	$ 2,008,843
Finance lease, right-of-use assets	$ 45,496
Acquisition of Montauk Brewing Company, Inc. [Member]
Cash					$ 28,701
Shares					6,422
Contingent consideration					10,245
Cash and cash equivalents					1,983
Accounts receivable					1,116
Prepaids and other current assets					467
Inventory					1,570
Capital assets					420
Goodwill					17,803
Total assets					55,549
Accounts payable and accrued liabilities					1,580
Deferred tax liability					4,851
Other liabilities					3,750
Total liabilities					10,181
Total net assets acquired					45,368
Acquisition of Montauk Brewing Company, Inc. [Member] \| Customer Relationships [Member]
Finite-lived intangible assets					18,540
Acquisition of Montauk Brewing Company, Inc. [Member] \| Intellectual Property, Trademarks and Brands [Member]
Finite-lived intangible assets					$ 13,650
HEXO [Member]
Shares				$ 63,927
Cash and cash equivalents				14,634
Accounts receivable				7,855
Prepaids and other current assets				2,709
Inventory				25,947
Capital assets				70,634
Finite-lived intangible assets				2,680
Accounts payable and accrued liabilities				44,517
Total liabilities				44,517
Total net assets acquired				93,882
Settlement of convertible notes receivable				28,720
Warrants assumed				47
Estimated fair value of HEXO stock-based compensation				1,188
Restricted cash				1,656
Asset held for sale				755
Prepaid expenses				8,384
Interest in equity investee				3,145
Total assets				$ 138,399
Truss Beverage Company [Member]
Cash		$ 74	$ 0.1
Cash and cash equivalents		6,739
Accounts receivable		1,038
Prepaids and other current assets		78
Inventory		2,573
Finite-lived intangible assets		296
Accounts payable and accrued liabilities		5,408
Total liabilities		6,284
Total net assets acquired		7,400
Asset held for sale		2,960
Total assets		13,684
Investment in equity investees		3,145
Other liabilities		876
Truss Beverage Company [Member] \| Contingent Consideration [Member]
Contingent consideration		$ 4,181
Craft Beverage Business Acquisition [Member]
Cash	83,658
Cash and cash equivalents	77
Prepaids and other current assets	573
Inventory	22,493
Capital assets	62,614
Accounts payable and accrued liabilities	2,206
Total liabilities	55,380
Total net assets acquired	83,658
Total assets	139,038
Operating lease, right-of-use assets	7,677
Other assets	108
Current portion of finance lease liabilities	1,031
Current portion of operating lease liabilities	1,408
Finance lease liabilities	44,465
Operating lease liabilities	$ 6,270

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023	May 31, 2023
Cash used in operating activities:
Net loss	$ (104,983)	$ (1,195,752)	$ (207,029)	$ (1,323,181)
Adjustments for:
Deferred income tax recovery			(7,399)	(29,537)
Unrealized foreign exchange (gain) loss			(6,622)	13,711
Amortization			95,183	101,156
Accretion of convertible debt discount			11,463	7,941
Inventory valuation write down			0	55,000
Impairments	0	934,000	0	934,000
Other than temporary change in fair value of convertible notes receivable	42,681	181,376	42,681	181,376
Other non-cash items			13,297	4,990
Stock-based compensation			24,517	29,766
(Gain) loss on long-term investments & equity investments			4,255	2,843
Loss on derivative instruments			13,717	13,534
Change in fair value of contingent consideration	(5,983)	352	(16,790)	563
Change in non-cash working capital:
Accounts receivable			5,578	18,053
Prepaids and other current assets			1,148	(32,680)
Inventory			(4,629)	(11,808)
Accounts payable and accrued liabilities			(30,982)	(1,419)
Net cash used in operating activities			(61,612)	(35,692)
Cash provided by (used in) investing activities:
Investment in capital and intangible assets			(19,539)	(8,394)
Proceeds from disposal of capital and intangible assets			1,166	2,175
Disposal (purchase) of marketable securities, net			162,292	(243,186)
Business acquisitions, net of cash acquired			(60,626)	(28,122)
Net cash provided by (used in) investing activities			83,293	(277,527)
Cash provided by (used in) financing activities:
Share capital issued, net of cash issuance costs			0	129,593
Shares effectively repurchased for employee withholding tax			0	(1,189)
Proceeds from long-term debt			32,621	1,288
Repayment of long-term debt			(17,978)	(64,658)
Proceeds from convertible debt			21,553	0
Repayment of convertible debt			(107,330)	0
Repayment of lease liabilities			(2,771)	(1,114)
Net increase (decrease) in bank indebtedness			(8,352)	2
Net cash provided by (used in) financing activities			(82,257)	63,922
Effect of foreign exchange on cash and cash equivalents			197	(1,615)
Net decrease in cash and cash equivalents			(60,379)	(250,912)
Cash and cash equivalents, beginning of period			206,632	415,909	$ 415,909
Cash and cash equivalents, end of period	$ 146,253	$ 164,997	$ 146,253	$ 164,997	$ 206,632

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies

9 Months Ended

Feb. 29, 2024

Basis of Presentation and Significant Accounting Policies [Text Block]

Note 1. Basis of presentation and summary of significant accounting policies

The accompanying unaudited condensed interim consolidated financial statements (the “financial statements”) reflect the accounts of the Company for the quarterly period ended February 29, 2024. The financial statements were prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and notes required by U.S. GAAP and should be read in conjunction with the audited consolidated financial statements (the “Annual Financial Statements”) included in the Company’s Annual Report on Form 10-K for the fiscal year ended May 31, 2023 (the “Annual Report”). These unaudited condensed interim consolidated financial statements reflect all adjustments, which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year.

These condensed interim consolidated financial statements have been prepared on the going concern basis which assumes that the Company will continue in operation for the foreseeable future and, accordingly, will be able to realize its assets and discharge its liabilities in the normal course of operations as they come due, under the historical cost convention except for certain financial instruments that are measured at fair value, as detailed in the Company’s accounting policies.

All amounts in the unaudited condensed interim consolidated financial statements, notes and tables have been rounded to the nearest thousand, except par values and per share amounts, and unless otherwise indicated.

Certain items of the comparative figures have been changed to conform to the presentation adopted in the current period.

Basis of consolidation

Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of all subsidiaries are included in the condensed interim consolidated financial statements from the date that control commences until the date that control ceases. All intercompany balances and transactions have been eliminated on consolidation. A complete list of our subsidiaries that existed as of our most recent fiscal year end is included in the Annual Report, except for the entities acquired within Note 7 (Business acquisitions) during the nine months ended February 29, 2024.

Marketable securities

We classify term deposits and other investments that have maturities of greater than three months but less than one year as marketable securities. The fair value of marketable securities is based on quoted market prices for publicly traded securities. Marketable securities are carried at fair value with changes in fair value recorded in the statement of net loss and comprehensive loss within the line “Non-operating income (expense), net”.

Restricted cash

We classify cash that is legally or contractually restricted as to withdrawal or usage as restricted cash. As of February 29, 2024, and May 31, 2023, the Company reported $nil restricted cash. During the six months ended November 31, 2023, the Company acquired $1,656 of restricted cash related to letters of credit and collateral from the acquisition of HEXO Corp. as described in Note 7 (Business acquisitions). During the three months ended February 29, 2024, all of the restricted cash was released and transferred to cash and cash equivalents.

Assets held for sale

We classify capital assets that are available for immediate sale in their present condition, which the Company has approved the action or plan to sell, and the sales is probable within one year, as assets held for sale. As of February 29, 2024, the Company reported $28,638 assets held for sale related to the Kirkland lake property, the Quebec cultivation facility and the Fort Collins facility, see Note 3 (Capital assets). Assets held for sale are to be measured at the lower of carrying amount and the fair value less costs to sell. Disposition of assets held for sale are recorded in the statement of net loss and comprehensive loss, within the line, “Non-operating income (expense)”.

When there are changes in circumstances that were previously considered unlikely to occur, and it is decided not to proceed with a sale, an asset that was previously classified as assets held for sale is reclassified as held and used. The asset is then remeasured at the lower of its carrying amount before being classified as held for sale less the amortization that would have occurred and the fair value on the date the decision not to proceed with a sale was made. Changes in the carrying amount are recorded in the statement of net loss and comprehensive loss.

Long-term investments

Investments in equity securities of entities over which the Company does not have a controlling financial interest or significant influence are classified as an equity investment and accounted for at fair value. Equity investments without readily determinable fair values are measured at cost with adjustments for observable changes in price or impairments (referred to as the “measurement alternative”). In applying the measurement alternative, the Company performs a qualitative assessment on a quarterly basis and recognizes an impairment if there are sufficient indicators that the fair value of an individual equity investment is less than its carrying value. Changes in value are recorded in the statement of net loss and comprehensive loss, within the line, “Non-operating income (expense), net”.

Investments in entities over which the Company does not have a controlling financial interest but has significant influence, are accounted for using the equity method, with the Company’s share of earnings or losses reported in earnings or losses from equity method investments on the consolidated statements of loss and comprehensive loss. Equity method investments are recorded at cost, adjusted for the Company’s share of undistributed earnings or losses, and impairment, if any, within “Interest in equity investees” on the balance sheets. The Company assesses investments in equity method investments when events or circumstances indicate that the carrying amount of the investment may be impaired. If it is determined that the current fair value of an equity method investment is less than the carrying value of the investment, the Company will assess if the shortfall is other than temporary (OTTI). Evidence of a loss in value might include, but would not necessarily be limited to, the absence of an ability to recover the carrying amount of the investment or inability of the equity investee to sustain an earnings capacity that would justify the carrying amount of the investment. Once a determination is made that an OTTI exists, the investment is written down to its fair value in accordance with ASC 820 Fair Value Measurement at the reporting date, which establishes a new cost basis.

Convertible notes receivable

Convertible notes receivable includes various investments in which the Company has the right, or potential right to convert the indenture into common stock of the investee and are classified as available-for-sale and are recorded at fair value. Unrealized gains and losses during the year, net of the related tax effect, are excluded from income and reflected in other comprehensive income (loss), and the cumulative effect is reported as a separate component of shareholders' equity until realized. We use judgement to assess convertible notes receivables for impairment at each measurement date. Convertible notes receivables are impaired when a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the consolidated statements of loss and comprehensive loss and a new cost basis for the investment is established. We also evaluate whether there is a plan to sell the security, or it is more likely than not that we will be required to sell the security before recovery. If neither of the conditions exist, then only the portion of the impairment loss attributable to credit loss is recorded in the statements of loss and the remaining amount is recorded in other comprehensive income (loss).

Revenue

Revenue is recognized when the control of the promised goods or services, through performance obligation, is transferred or provided to the customer in an amount that reflects the consideration we expect to be entitled to in exchange for the performance obligations.

Excise taxes remitted to tax authorities are government-imposed excise taxes on cannabis and beer. Excise taxes are recorded as a reduction of sales in net revenue in the consolidated statements of loss and comprehensive loss and recognized as a current liability within accounts payable and accrued liabilities on the consolidated balance sheets, with the liability subsequently reduced when the taxes are remitted to the tax authority.

In addition, amounts disclosed as net revenue are net of excise taxes, sales tax, duty tax, allowances, discounts and rebates.

In determining the transaction price for the sale of goods or services, the Company considers the effects of variable consideration and the existence of significant financing components, if any.

We may enter into certain contracts for the sale of goods or services, which provide customers with rights of return, volume discounts, bonuses for volume/quality achievement, and/or sales allowances. In addition, the Company may provide in certain circumstances, a retrospective price reduction to a customer based primarily on inventory movement. The inclusion of these items may give rise to variable consideration. The Company uses the expected value method to estimate the variable consideration because this method provides the most accurate estimation of the amount of variable consideration to which the Company will be entitled. The Company uses historical evidence, current information and forecasts to estimate the variable consideration. The Company reduces revenue and recognizes a contract liability, recorded in accounts receivable, net, equal to the amount expected to be refunded to the customer in the form of a future rebate or credit for a retrospective price reduction, representing its obligation to return the customer’s consideration. The estimate is updated at each reporting period date.

On July 12, 2022, the Company and HEXO Corp. ("HEXO") entered into various commercial transaction agreements, as described in Note 26 (Segment reporting), which included an advisory services arrangement. The fees associated with the advisory services arrangement were recognized as revenue when such services were provided to HEXO. Any payments that were received for such services in advance of performance were recognized as a contract liability. On June 22, 2023, the Company completed the acquisition of HEXO, as described in Note 7 (Business acquisitions), simultaneously terminating the advisory services arrangement and other commercial transactions.

Transaction (income) costs

The Company expenses costs net of any gains directly attributable to business acquisitions and classifies these items as transaction (income) costs. These items include among other things, legal fees to complete the acquisition, financial advisor and due diligence costs, and transaction related compensation. These items are recognized as incurred.

Earnings (loss) per share

Basic earnings (loss) per share is computed by dividing reported net income (loss) attributable to stockholders of Tilray Brands, Inc. by the weighted average number of common shares outstanding during the year. Diluted earnings (loss) per share is computed by dividing reported net income (loss) attributable to stockholders of Tilray Brands, Inc. by the sum of the weighted average number of common shares and the number of dilutive potential common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options, warrants, and RSUs and the incremental shares issuable upon conversion of the convertible debentures and similar instruments. Shares of common stock outstanding under the share lending arrangement entered into in conjunction with the TLRY 27 Notes, see Note 13 (Convertible debentures payable) are excluded from the calculation of basic and diluted earnings per share because the borrower of the shares is required under the share lending arrangement to refund any dividends paid on the shares lent.

In computing diluted earnings (loss) per share, common share equivalents are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. For the three and nine months ended February 29, 2024 and February 28, 2023, the dilutive potential common share equivalents outstanding consisted of the following: 20,652,315 and 16,431,876 common shares from RSUs, 5,744,302 and 4,660,046 common shares from share options, 6,209,000 and 6,209,000 common shares for warrants and 72,653,364 and 36,388,651 common shares for convertible debentures, respectively.

New accounting pronouncements not yet adopted

In August 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-05, Business Combination - Joint Venture Formations (Subtopic 805-60) Recognition and Initial Measurement (“ASU 2023-05”), which is intended to address the accounting for contributions made to a joint venture. ASU 2023-05 is effective for the Company beginning June 1, 2026. This update will be applied prospectively on or after the effective date of the amendments. The Company is currently evaluating the effect of adopting this ASU.

In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative, which amends the disclosure or presentation requirements related to various subtopics in the FASB Accounting Standards Codification (the “Codification”). The effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. If by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective for any entity. The Company is currently evaluating the effect of adopting this ASU.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments’ significant expenses on an interim and annual basis. ASU 2023-07 is effective for the Company beginning the year ended May 31, 2025. The Company is currently evaluating the effect of adopting this ASU.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) Improvements to Income Tax Disclosures, which requires public entities to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis. ASU 2023-09 is effective for the Company beginning the year ended June 01, 2024. The Company is currently evaluating the effect of adopting this ASU.

New accounting pronouncements recently adopted

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Subtopic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency. The Company adopted the ASU 2021-08 beginning June 1, 2023, however, it did not have any impact on our condensed interim consolidated financial statements.

Note 7 - Business Acquisitions (Details Textual) $ / shares in Units, $ in Thousands, $ in Millions						3 Months Ended		9 Months Ended
	Sep. 29, 2023 USD ($)	Aug. 03, 2023 USD ($)	Aug. 03, 2023 CAD ($)	Jun. 22, 2023 USD ($) $ / shares shares	Nov. 07, 2022 USD ($) shares	Feb. 29, 2024 USD ($)	Feb. 28, 2023 USD ($)	Feb. 29, 2024 USD ($)	Feb. 28, 2023 USD ($)
Business Acquisition, Pro Forma Net Income (Loss)							$ 600		$ 1,800
Acquisition of Montauk Brewing Company, Inc. [Member]
Business Combination, Consideration Transferred					$ 35,123
Payments to Acquire Businesses, Gross					28,701
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable					6,422
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High					18,000
Business Combination, Contingent Consideration, Liability, Total					10,245
Business Acquisition, Pro Forma Revenue							3,100		12,100
Business Acquisition, Pro Forma Net Income (Loss)							(600)		1,100
Business Combination, Consideration Transferred, Liabilities Incurred					$ 10,245
Acquisition of Montauk Brewing Company, Inc. [Member] \| Common Class 2 [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) \| shares					1,708,521
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable					$ 6,422
HEXO [Member]
Business Combination, Consideration Transferred				$ 93,882
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) \| shares				39,705,962
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable				$ 63,927
Business Acquisition, Pro Forma Revenue						$ 0	15,000	$ 7,000	55,000
Business Acquisition, Pro Forma Net Income (Loss)						0	25,000	1,800	85,000
Business Combination, Consideration Transferred, Settlement of Convertible Notes Receivable				28,720
Business Combination, Consideration Transferred, Fair Value of Stock Based Compensation				1,188
Business Combination, Consideration Transferred, Warrants Assumed				$ 47
Business Combination, Common Share Exchange Ratio				0.4352
Business Combination, Preferred Share Exchange Ratio				0.7805
Business Acquisition, Share Price (in dollars per share) \| $ / shares				$ 1.61
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Litigation Settlement Accruals				$ 12,253
Truss Beverage Company [Member]
Payments to Acquire Businesses, Gross		$ 74	$ 0.1
Business Acquisition, Pro Forma Revenue						0		3,000
Business Acquisition, Pro Forma Net Income (Loss)						0	4,600	700	10,900
Business Acquisition, Percentage of Voting Interests Acquired		57.50%	57.50%
Truss Beverage Company [Member] \| Contingent Consideration [Member]
Business Combination, Consideration Transferred, Liabilities Incurred		$ 4,181
Business Combination, Contingent Consideration, Liability, Settlement Payment						760
Business Combination, Contingent Consideration, Gain/(Loss) from Change in Fair Value						3,683
Foreign Exchange Impact						262		262
Craft Beverage Business Acquisition [Member]
Payments to Acquire Businesses, Gross	$ 83,658
Business Acquisition, Pro Forma Revenue						0	33,000	55,000	118,000
Business Acquisition, Pro Forma Net Income (Loss)						$ 0	$ 3,500	$ 5,000	$ 4,400
Number of Brands Acquired	8
Working Capital Adjustment	$ 1,342
Craft Beverage Business Acquisition [Member] \| Delayed Draw Term Loan Agreement [Member]
Long-Term Debt	$ 20,000

Note 16 - Accumulated Other Comprehensive Income (Loss) (Tables)

9 Months Ended

Feb. 29, 2024

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

				*Unrealized*
	*Foreign*			*loss on*
	*currency*			*convertible*
	*translation*			*notes*
	*gain (loss)*			*receivables*			*Total*
Balance May 31, 2022	$	54,413		$	(75,177	)	$	(20,764	)
Other comprehensive loss		(56,443	)		(2,525	)		(58,968	)
Balance August 31, 2022	$	(2,030	)	$	(77,702	)	$	(79,732	)
Other comprehensive loss		(24,080	)		(17,643	)		(41,723	)
Balance November 30, 2022	$	(26,110	)	$	(95,345	)	$	(121,455	)
Other comprehensive (loss) reversal		(16,838	)		95,345			78,507
Balance February 28, 2023	$	(42,948	)	$	—		$	(42,948	)

Balance May 31, 2023	$	(46,610	)	$	—		$	(46,610	)
Other comprehensive loss		3,049			—			3,049
Balance August 31, 2023	$	(43,561	)	$	—		$	(43,561	)
Other comprehensive loss		5,194			—			5,194
Balance November 30, 2023	$	(38,367	)	$	—		$	(38,367	)
Other comprehensive loss		(4,820	)		—			(4,820	)
Balance February 29, 2024	$	(43,187	)	$	—		$	(43,187	)

Note 18 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
Income Tax Expense (Benefit)	$ (2,871)	$ (10,811)	$ 1,013	$ (15,313)

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

Note 17 - Non-controlling Interests (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023	Aug. 31, 2021
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest	$ (12,158)	$ (1,526)	$ 6,498	$ 9,624
Subsidiaries [Member]
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest			$ 1,162	656
Subsidiaries [Member] \| Wholesale Cannabis Supply Agreement [Member]
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest	$ (15,000)
Superhero Acquisition LP [Member]
Noncontrolling Interest, Ownership Percentage by Parent	68.00%		68.00%		68.00%
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest			$ (13,658)	(11,686)
CC Pharma Nordic ApS [Member]
Noncontrolling Interest, Ownership Percentage by Parent	75.00%		75.00%
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest			$ 267	(137)
Aphria Diamond [Member]
Noncontrolling Interest, Ownership Percentage by Parent	51.00%		51.00%
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest			$ 14,527	21,544
ColCanna S.A.S. [Member]
Noncontrolling Interest, Ownership Percentage by Parent	90.00%		90.00%
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest			$ 26	$ (9,065)

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	HT Investments MA LLC Note [Member] Common Stock and Preferred Stock [Member]	HT Investments MA LLC Note [Member] Additional Paid-in Capital [Member]	HT Investments MA LLC Note [Member] AOCI Attributable to Parent [Member]	HT Investments MA LLC Note [Member] Retained Earnings [Member]	HT Investments MA LLC Note [Member] Noncontrolling Interest [Member]	HT Investments MA LLC Note [Member]	TLRY 27 [Member] Common Stock and Preferred Stock [Member]	TLRY 27 [Member] Additional Paid-in Capital [Member]	TLRY 27 [Member] AOCI Attributable to Parent [Member]	TLRY 27 [Member] Retained Earnings [Member]	TLRY 27 [Member] Noncontrolling Interest [Member]	TLRY 27 [Member]	Acquisition of Montauk Brewing Company, Inc. [Member] Common Stock and Preferred Stock [Member]	Acquisition of Montauk Brewing Company, Inc. [Member] Additional Paid-in Capital [Member]	Acquisition of Montauk Brewing Company, Inc. [Member] AOCI Attributable to Parent [Member]	Acquisition of Montauk Brewing Company, Inc. [Member] Retained Earnings [Member]	Acquisition of Montauk Brewing Company, Inc. [Member] Noncontrolling Interest [Member]	Acquisition of Montauk Brewing Company, Inc. [Member]	HEXO Acquisition [Member] Common Stock and Preferred Stock [Member]	HEXO Acquisition [Member] Additional Paid-in Capital [Member]	HEXO Acquisition [Member] AOCI Attributable to Parent [Member]	HEXO Acquisition [Member] Retained Earnings [Member]	HEXO Acquisition [Member] Noncontrolling Interest [Member]	HEXO Acquisition [Member]	Tilray Brands Inc MediPharm / HEXO Litigation Settlement [Member] Common Stock and Preferred Stock [Member]	Tilray Brands Inc MediPharm / HEXO Litigation Settlement [Member] Additional Paid-in Capital [Member]	Tilray Brands Inc MediPharm / HEXO Litigation Settlement [Member] AOCI Attributable to Parent [Member]	Tilray Brands Inc MediPharm / HEXO Litigation Settlement [Member] Retained Earnings [Member]	Tilray Brands Inc MediPharm / HEXO Litigation Settlement [Member] Noncontrolling Interest [Member]	Tilray Brands Inc MediPharm / HEXO Litigation Settlement [Member]	Common Stock and Preferred Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at May. 31, 2022																															532,674,887
Balance at May. 31, 2022																															$ 53	$ 5,382,367	$ (20,764)	$ (962,851)	$ 42,561	$ 4,441,366
Share issuance - equity financing (in shares)																															32,481,149
Share issuance - equity financing																															$ 3	129,590	0	0	0	129,593
Shares issued to purchase HEXO convertible note receivable (in shares)																															33,314,412
Shares issued to purchase HEXO convertible note receivable																															$ 3	107,269	0	0	0	107,272
HTI Convertible Note - conversion feature	$ 0	$ 9,055	$ 0	$ 0	$ 0	$ 9,055
Share issuance - Double Diamond Holdings dividend settlement (in shares)																															1,529,821
Share issuance - Double Diamond Holdings dividend settlement																															$ 1	5,063	0	0	0	5,064
Share issuance - options exercised (in shares)																															3,777
Share issuance - options exercised																															$ 0	0	0	0	0	0
Share issuance - RSUs exercised (in shares)																															950,893
Share issuance - RSUs exercised																															$ 0	0	0	0	0	0
Shares effectively repurchased for employee withholding tax																															0	(1,189)	0	0	0	(1,189)
Stock-based compensation																															0	9,193	0	0	0	9,193
Dividends declared to non-controlling interests																															0	0	0	0	(8,561)	(8,561)
Net comprehensive (loss) income																															$ 0	0	(58,968)	(73,482)	3,839	(128,611)
Share issuance - Settlement of equity component of TLRY 23 convertible note	$ 0	$ (9,055)	$ 0	$ 0	$ 0	$ (9,055)
Balance (in shares) at Aug. 31, 2022																															600,954,939
Balance at Aug. 31, 2022																															$ 60	5,641,348	(79,732)	(1,036,333)	37,839	4,563,182
Balance (in shares) at May. 31, 2022																															532,674,887
Balance at May. 31, 2022																															$ 53	5,382,367	(20,764)	(962,851)	42,561	4,441,366
Net comprehensive (loss) income																																				(1,326,503)
Balance (in shares) at Feb. 28, 2023																															617,977,031
Balance at Feb. 28, 2023																															$ 62	5,723,342	(42,948)	(2,276,794)	3,109	3,406,771
Balance (in shares) at Aug. 31, 2022																															600,954,939
Balance at Aug. 31, 2022																															$ 60	5,641,348	(79,732)	(1,036,333)	37,839	4,563,182
Share issuance - Double Diamond Holdings dividend settlement (in shares)																															10,276,305
Share issuance - Double Diamond Holdings dividend settlement																															$ 1	38,753	0	0	(32,280)	6,474
Share issuance - options exercised (in shares)																															4,183
Share issuance - options exercised																															$ 0	0	0	0	0	0
Share issuance - RSUs exercised (in shares)																															237,611
Share issuance - RSUs exercised																															$ 0	0	0	0	0	0
Stock-based compensation																															0	10,943	0	0	0	10,943
Net comprehensive (loss) income																															$ 0	0	(41,723)	(69,463)	7,311	(103,875)
Shares issuance (in shares)													1,708,521
Shares issuance													$ 0	$ 6,422	$ 0	$ 0	$ 0	$ 6,422
Balance (in shares) at Nov. 30, 2022																															613,181,559
Balance at Nov. 30, 2022																															$ 61	5,697,466	(121,455)	(1,105,796)	12,870	4,483,146
Share issuance - Double Diamond Holdings dividend settlement (in shares)																															4,188,280
Share issuance - Double Diamond Holdings dividend settlement																															$ 1	15,912	0	0	(8,235)	7,678
Share issuance - RSUs exercised (in shares)																															487,192
Share issuance - RSUs exercised																															$ 0	0	0	0	0	0
Stock-based compensation																															0	9,630	0	0	0	9,630
Net comprehensive (loss) income																															$ 0	0	78,507	(1,170,998)	(1,526)	(1,094,017)
Preferred share issuance (in shares)																															120,000
Preferred share issuance																															$ 0	334	0	0	0	334
Balance (in shares) at Feb. 28, 2023																															617,977,031
Balance at Feb. 28, 2023																															$ 62	5,723,342	(42,948)	(2,276,794)	3,109	3,406,771
Balance (in shares) at May. 31, 2023																															656,655,455
Balance at May. 31, 2023																															$ 66	5,777,743	(46,610)	(2,415,507)	14,251	3,329,943
Share issuance - Double Diamond Holdings dividend settlement (in shares)																															5,004,735
Share issuance - Double Diamond Holdings dividend settlement																															$ 0	8,146	0	0	0	8,146
Share issuance - RSUs exercised (in shares)																															3,912,481
Share issuance - RSUs exercised																															$ 0	0	0	0	0	0
Shares effectively repurchased for employee withholding tax																															0	(4,860)	0	0	0	(4,860)
Stock-based compensation																															0	8,257	0	0	0	8,257
Dividends declared to non-controlling interests																															0	0	0	0	(7,891)	(7,891)
Net comprehensive (loss) income																															$ 0	0	3,049	(71,525)	15,822	(52,654)
Shares issuance (in shares)																			39,705,962
Shares issuance																			$ 4	$ 65,158	$ 0	$ 0	$ 0	$ 65,162
Share issuance - acquisition settlement (in shares)																															865,426
Share issuance - acquisition settlement							$ 0	$ 3,953	$ 0	$ 0	$ 0	$ 3,953																			$ 0	1,500	0	0	0	1,500
Share issuance (in shares)																															17,148,541
Share issuance - HTI convertible note																															$ 2	49,998				50,000
Share issuance - HTI convertible note (in shares)																															17,148,541
Balance (in shares) at Aug. 31, 2023																															723,292,600
Balance at Aug. 31, 2023																															$ 72	5,909,895	(43,561)	(2,487,032)	22,182	3,401,556
Balance (in shares) at May. 31, 2023																															656,655,455
Balance at May. 31, 2023																															$ 66	5,777,743	(46,610)	(2,415,507)	14,251	3,329,943
Net comprehensive (loss) income																																				(203,313)
Balance (in shares) at Feb. 29, 2024																															774,028,053
Balance at Feb. 29, 2024																															$ 77	6,030,709	(43,187)	(2,628,741)	(15,817)	3,343,041
Balance (in shares) at Aug. 31, 2023																															723,292,600
Balance at Aug. 31, 2023																															$ 72	5,909,895	(43,561)	(2,487,032)	22,182	3,401,556
HTI Convertible Note - conversion feature																															$ (0)	1,672	(0)	(0)	(0)	1,672
Share issuance - RSUs exercised (in shares)																															9,184
Share issuance - RSUs exercised																															$ 0	0	0	0	0	0
Stock-based compensation																															0	8,201	0	0	0	8,201
Net comprehensive (loss) income																															$ 0	0	5,194	(49,008)	2,834	(40,980)
Share issuance (in shares)																															1,032,616
Share issuance - HTI convertible note																															$ 0	2,313	0	0	0	2,313
Share issuance - HTI convertible note (in shares)																															1,032,616
Share issuance - Settlement of litigation claims from MediPharm Labs Inc (in shares)																									1,573,152
Share issuance - Settlement of litigation claims from MediPharm Labs Inc																									$ 0	$ 3,477	$ 0	$ 0	$ 0	$ 3,477
Share issuance - Repurchase of TLRY 23 convertible note (in shares)																															7,000,000
Share issuance - Repurchase of TLRY 23 convertible note																															$ 1	20,457	0	0	0	20,458
Share issuance - Settlement of equity component of TLRY 23 convertible note																															$ 0	(1,672)	0	0	0	(1,672)
Balance (in shares) at Nov. 30, 2023																															732,907,552
Balance at Nov. 30, 2023																															$ 73	5,942,671	(38,367)	(2,536,040)	25,016	3,393,353
Share issuance - Double Diamond Holdings dividend settlement (in shares)																															13,627,391
Share issuance - Double Diamond Holdings dividend settlement																															$ 1	28,599	0	0	(26,217)	2,383
Share issuance - options exercised (in shares)																															4,291
Share issuance - options exercised																															$ 0	0	0	0	0	0
Share issuance - RSUs exercised (in shares)																															260,567
Share issuance - RSUs exercised																															$ 0	0	0	0	0	0
Stock-based compensation																															0	8,059	0	0	0	8,059
Dividends declared to non-controlling interests																															0	0	0	0	(2,458)	(2,458)
Net comprehensive (loss) income																															$ 0	0	(4,820)	(92,701)	(12,158)	(109,679)
Share issuance - HTI convertible note																																				2,313
Share issuance - Repurchase of TLRY 23 convertible note (in shares)																															27,228,252
Share issuance - Repurchase of TLRY 23 convertible note																															$ 3	51,380	0	0	0	51,383
Balance (in shares) at Feb. 29, 2024																															774,028,053
Balance at Feb. 29, 2024																															$ 77	$ 6,030,709	$ (43,187)	$ (2,628,741)	$ (15,817)	$ 3,343,041

Note 19 - Commitments and Contingencies

9 Months Ended

Feb. 29, 2024

Commitments and Contingencies Disclosure [Text Block]

Note 19. Commitments and contingencies

Purchase and other commitments

The Company has payments on long-term debt, refer to Note 12 (Long-term debt), convertible notes, refer to Note 13 (Convertible debentures payable), material purchase commitments and construction commitments as follows:

	*Total*		*2024*		*2025*		*2026*		*2027*		*Thereafter*
Long-term debt repayment	$	178,977	$	12,535	$	44,319	$	8,973	$	10,335	$	102,815
Convertible debentures payable		258,530		86,030		—		—		172,500		—
Material purchase obligations		49,159		21,587		27,572		—		—		—
Construction commitments		822		822		—		—		—		—
Total	$	487,488	$	120,974	$	71,891	$	8,973	$	182,835	$	102,815

Legal proceedings

In the ordinary course of business, we are at times subject to various legal proceedings and disputes, including the proceedings specifically discussed below. We assess our liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that we will incur a loss and the amount of the loss can be reasonably estimated, we record a liability in our consolidated financial statements. These legal reserves may be increased or decreased to reflect any relevant developments on a quarterly basis. Where a loss is not probable or the amount of loss is not estimable, we do not accrue legal reserves. While the outcome of legal proceedings is inherently uncertain, based on information currently available and available insurance coverage, our management believes that it has established appropriate legal reserves. Any incremental liabilities arising from pending legal proceedings are not expected to have a material adverse effect on our consolidated financial position, consolidated results of operations, or consolidated cash flows. However, it is possible that the ultimate resolution of these matters, if unfavorable, may be material to our consolidated financial position, consolidated results of operations, or consolidated cash flows.

There have been no material changes from the legal proceedings since our Annual Report on Form 10-K for the fiscal year ended May 31, 2023, except with respect to certain aspects of the legal proceedings disclosed below:

420 Investments Ltd. Litigation

On February 21, 2020, 420 Investments Ltd., as Plaintiff (“420 Investments”), filed a lawsuit against Tilray Brands, Inc. and High Park Shops Inc. as Defendants, in Calgary, Alberta in the Court of Queen’s Bench of Alberta. In August 2019, Tilray and High Park entered into an Arrangement Agreement with 420 Investments and others (the “420 Arrangement Agreement”). Pursuant to the 420 Arrangement Agreement, High Park was to acquire the securities of 420 Investments. In February 2020, Tilray and High Park gave notice of termination of the 420 Agreement due to 420 Investment’s breach and failure to satisfy certain conditions precedent. 420 Investments alleges that the termination was unlawful and without merit and further alleges that the Defendants had no legal basis to terminate. 420 Investment seeks damages in the stated amount of C$110,000, plus C$20,000 in aggravated damages. Discoveries are continuing in this litigation proceeding. Tilray and High Park deny the Plaintiff’s allegations and intend to continue to vigorously defend this litigation matter, although there can be no assurance as to its outcome.

In February 2023, Tilray and High Park filed an Application for Summary Judgment to collect an unpaid C$7,000 bridge loan made to 420 Investments on August 28, 2019. That debt was repayable in March 2020, but was never repaid by 420 Investments. On February 8, 2024, the Court granted Tilray and High Park’s summary judgment application, holding that Tilray and High Park were entitled to be paid the full amount of the C$7,000 bridge loan, see Note 22 (General and administrative expenses), plus on-going interest C$2,800 and costs. Tilray intends to pursue full collection of this judgment as it continues to defend the main proceedings regarding termination of the 420 Arrangement Agreement.

Cannfections Group Inc. / High Park Farms Ltd. (Canada, Commercial Arbitration).

On December 2, 2022 Cannfections Group Inc. (“Cannfections”), a joint venture that is 50% owned by High Park Farms, Ltd., delivered a Request to Arbitrate along with a Statement of Claim to Tilray’s subsidiaries High Park Farms Ltd. (“HP Farms”) and High Park Holdings Ltd. (“HP Holdings”) for an arbitration to be held in Toronto, Ontario. Cannfections claimed breach of contract against HP Farms and HP Holdings arising from a 2019 supply agreement pursuant to which Cannfections manufactured cannabis-infused chocolates and gummies. Cannfections primarily alleged that HP Farms failed to meet certain minimum order volumes of products from Cannfections resulting in claimed damages of C$27,500. HP Farms filed a Statement of Defense denying the allegations as part of an Arbitration proceeding held in November 2023. HP Farms believed these claims were without merit and vigorously defended the claims during arbitration proceeding. However, on March 5, 2024, the Arbitrator issued a Decision awarding Cannfections damages in the amount of C$19,950 plus interest. The Arbitrator also determined that HP Holdings was not a proper party to the Arbitration and dismissed all claims against HP Holdings.

On April 5, 2024, HP Farms commenced a voluntary assignment in bankruptcy, naming B. Riley Farber as its licensed insolvency trustee. HP Farms’ bankruptcy filing is limited solely to HP Farms, and neither Tilray nor any of its affiliates are petitioners or parties to the HP Farms bankruptcy filing. As a result of this bankruptcy filing, the Company recognized $4,638 for a decrease in value of the equity investee during the three months ended February 29, 2024. The Company does not expect that there will be any further impact to the Company’s financial statements. HP Farms determined to commence bankruptcy proceedings given it ceased all active operations following closure of the Enniskillen facility and the termination of its supply agreement with Cannfections. The purpose of the bankruptcy filing is to ensure the orderly liquidation and wind-up of HP Farms’ remaining assets and liabilities. See Note 24 (Non-operating income (expense)).

Summary of litigation accruals

As described in Note 11 (Accounts payable and accrued liabilities), the total litigation expense accrual included in accrued liabilities as of February 29, 2024 was $25,153 to cover various ongoing litigation matters that are probable and estimable ( May 31, 2023 - $25,000). During the nine months ended February 29, 2024, the Company assumed $12,253 of litigation accruals from the acquisition of HEXO, several of which were settled during the nine months ended February 29, 2024. The Company did not assume any litigation accruals from the Craft Acquisition.

Note 20 - Net Revenue (Tables)

9 Months Ended

Feb. 29, 2024

Disaggregation of Revenue [Table Text Block]

	*For the three months ended*						*For the nine months ended*
	*February 29,*			*February 28,*			*February 29,*			*February 28,*
	*2024*			*2023*			*2024*			*2023*
Beverage alcohol revenue	$	58,247		$	21,941		$	133,237		$	67,209
Beverage alcohol excise taxes		(3,559	)		(1,301	)		(7,882	)		(4,520	)
Net beverage alcohol revenue		54,688			20,640			125,355			62,689
Cannabis revenue		85,236			61,118			276,676			203,503
Cannabis excise taxes		(21,804	)		(13,569	)		(75,797	)		(47,486	)
Net cannabis revenue		63,432			47,549			200,879			156,017
Distribution revenue		56,794			65,385			193,174			186,158
Wellness revenue		13,426			12,015			39,652			38,072
Total	$	188,340		$	145,589		$	559,060		$	442,936

Note 21 - Cost of Goods Sold - Components of Cost of Goods Sold (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
Cost of goods sold	$ 138,944	$ 157,288	$ 418,059	$ 363,139
Beverage Alcohol Business [Member]
Cost of goods sold	35,836	10,663	77,615	32,932
Cannabis Segment [Member]
Cost of goods sold	42,518	80,362	139,507	137,800
Tilray Pharma Segment [Member]
Cost of goods sold	51,231	57,964	172,846	165,443
Wellness Business [Member]
Cost of goods sold	$ 9,359	$ 8,299	$ 28,091	$ 26,964

Note 7 - Business Acquisitions - Assets Acquired and Liabilities Assumed (Details) (Parentheticals)	Jun. 22, 2023	Nov. 07, 2022
Acquisition of Montauk Brewing Company, Inc. [Member] \| Customer Relationships [Member]
Estimated useful life (Year)		15 years
Acquisition of Montauk Brewing Company, Inc. [Member] \| Intellectual Property, Trademarks and Brands [Member]
Estimated useful life (Year)		15 years
HEXO [Member]
Estimated useful life (Year)	15 years

Note 15 - Stockholders' Equity (Details Textual) - USD ($) $ in Thousands				3 Months Ended					9 Months Ended		12 Months Ended
	Oct. 02, 2023	Sep. 12, 2023	Jul. 12, 2022	Feb. 29, 2024	Aug. 31, 2023	Feb. 28, 2023	Nov. 30, 2022	Aug. 31, 2022	Feb. 29, 2024	Feb. 28, 2023	May 31, 2023
Common Stock, Shares Authorized (in shares)				1,198,000,000					1,198,000,000		1,198,000,000
Preferred Stock, Shares Authorized (in shares)				10,000,000					10,000,000		10,000,000
Common Stock, Shares, Issued (in shares)				774,028,053					774,028,053		656,655,455
Preferred Stock, Shares Issued (in shares)				0					0		0
Stock Issued During Period, Value, Settlement of Financing Liability				$ 2,383	$ 8,146	$ 7,678	$ 6,474	$ 5,064
Repayments of Convertible Debt									$ 107,330	$ (0)
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture (in shares)									4,186,523
Share-Based Payment Arrangement, Expense				$ 8,059		$ 9,630			$ 24,517	$ 29,766
Common Stock, Shares, Outstanding (in shares)				774,028,053					774,028,053		656,655,455
Preferred Stock, Shares Outstanding (in shares)				0					0		0
Time-based Restricted Stock Units [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)									11,559,549	6,004,995
Performance-based Restricted Stock Units [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)									7,566,146	2,634,744
HT Investments MA LLC Note [Member]
Stock Issued During Period, Shares, For Derivative Settlement (Downside Protection) (in shares)									17,148,541
HT Investments MA LLC Note [Member] \| Derivative Settlement [Member]
Stock Issued During Period, Shares, For Derivative Settlement (Downside Protection) (in shares)									1,032,616
HTI Convertible Note Payable [Member]
Repayments of Convertible Debt			$ 50,000
Tilray Brands Inc MediPharm / HEXO Litigation Settlement [Member]
Stock Issued During Period, Shares, Legal Settlement (in shares)									1,573,152
TLRY 23 [Member]
Repayments of Convertible Debt	$ 107,330	$ 610		$ (0)							$ 150,526
Stock Issued During Period, Shares, For The Repayment of Convertible Debt (in shares)		7,000,000							7,000,000
Convertible Debt Instrument, Repurchase Amount				20,000					$ 20,000
APHA 24 [Member]
Repayments of Convertible Debt				$ 263,970							$ 213,260
Stock Issued During Period, Shares, For The Repayment of Convertible Debt (in shares)				27,228,252					27,228,252
Convertible Debt Instrument, Repurchase Amount				$ 50,710					$ 50,710
Aphria Diamond [Member]
Stock Issued During Period, Shares, Settlement of Dividend Payable (in shares)									18,632,126
HEXO [Member]
Stock Issued During Period, Shares, Purchase of Assets (in shares)									39,705,962
Stock Issued During Period, Shares, Settlement of Financing Liability (in shares)									865,426
Stock Issued During Period, Value, Settlement of Financing Liability									$ 1,500

Note 11 - Accounts Payable and Accrued Liabilities

9 Months Ended

Feb. 29, 2024

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Note 11. Accounts payable and accrued liabilities

Accounts payable and accrued liabilities are comprised of:

	*February 29,*		*May 31,*
	*2024*		*2023*
Trade payables	$	90,163	$	70,819
Accrued liabilities		70,744		48,394
Litigation accrual		25,153		25,000
Accrued payroll and employment related taxes		14,993		18,772
Income taxes payable		1,438		14,934
Accrued interest		3,202		8,102
Sales taxes payable		4,070		4,661
Total	$	209,763	$	190,682

Note 13 - Convertible Debentures Payable (Tables)

9 Months Ended

Feb. 29, 2024

Convertible Debt [Table Text Block]

	*February 29,*		*May 31,*
	*2024*		*2023*
5.20% Convertible Notes ("TLRY 27")	$	126,587	$	100,476
HTI Convertible Note		—		47,834
5.25% Convertible Notes ("APHA 24")		83,351		120,568
5.00% Convertible Notes ("TLRY 23")		—		126,544
Total		209,938		395,422
Deduct - current portion		83,351		174,378
Total convertible debentures payable, non current portion	$	126,587	$	221,044

	*February 29,*			*May 31,*
	*2024*			*2023*
5.20% Contractual debenture	$	172,500		$	150,000
Unamortized discount		(45,913	)		(49,524	)
Net carrying amount	$	126,587		$	100,476

	*February 29,*		May 31,
	*2024*		*2023*
4.00% Contractual debenture	$	—	$	50,000
Unamortized discount		—		(2,166	)
Net carrying amount	$	—	$	47,834

	*February 29,*			*May 31,*
	*2024*			*2023*
5.25% Contractual debenture	$	350,000		$	350,000
Debt settlement		(263,970	)		(213,260	)
Fair value adjustment		(2,679	)		(16,172	)
Net carrying amount	$	83,351		$	120,568

	*February 29,*		*May 31,*
	*2024*		*2023*
5.00% Contractual debenture	$	—	$	277,856
Principal amount paid		—		(150,526	)
Unamortized discount		—		(786	)
Net carrying amount	$	—	$	126,544

Note 26 - Segment Reporting

9 Months Ended

Feb. 29, 2024

Segment Reporting Disclosure [Text Block]

Note 26. Segment reporting

Information reported to the Chief Operating Decision Maker (“CODM”) for the purpose of resource allocation and assessment of segment performance focuses on the nature of the operations. The Company operates in four reportable segments: (1) beverage alcohol operations, which encompasses the production, marketing and sale of beverage and beverage alcohol products, (2) cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis, (3) distribution operations, which encompasses the purchase and resale of pharmaceuticals products to wholesale and pharmacy customers, and (4) wellness products, which encompasses hemp foods and hemp-based cannabidiol (“CBD”) consumer products. This structure is in line with how our Chief Operating Decision Maker (“CODM”) assesses our performance and allocates resources.

Operating segments have not been aggregated and no asset information is provided for the segments because the Company’s CODM does not receive asset information by segment on a regular basis.

Segment gross profit from external customers:

	*For the three months ended*					*For the nine months ended*
	*February 29,*		*February 28,*			*February 29,*		*February 28,*
	*2024*		*2023*			*2024*		*2023*
Beverage alcohol
Net beverage alcohol revenue	$	54,688	$	20,640		$	125,355	$	62,689
Beverage alcohol costs		35,836		10,663			77,615		32,932
Beverage alcohol gross profit		18,852		9,977			47,740		29,757
Cannabis
Net cannabis revenue		63,432		47,549			200,879		156,017
Cannabis costs		42,518		80,362			139,507		137,800
Cannabis gross profit (loss)		20,914		(32,813	)		61,372		18,217
Distribution
Distribution revenue		56,794		65,385			193,174		186,158
Distribution costs		51,231		57,964			172,846		165,443
Distribution gross profit		5,563		7,421			20,328		20,715
Wellness
Wellness revenue		13,426		12,015			39,652		38,072
Wellness costs		9,359		8,299			28,091		26,964
Wellness gross profit	$	4,067	$	3,716		$	11,561	$	11,108

Channels of Cannabis revenue were as follows:

	*For the three months ended*						*For the nine months ended*
	*February 29,*			*February 28,*			*February 29,*			*February 28,*
	*2024*			*2023*			*2024*			*2023*
Revenue from Canadian medical cannabis	$	6,363		$	6,035		$	18,793		$	18,920
Revenue from Canadian adult-use cannabis		62,107			45,318			205,350			156,063
Revenue from wholesale cannabis		2,764			58			12,348			686
Revenue from international cannabis		14,002			9,707			40,185			27,834
Less excise taxes		(21,804	)		(13,569	)		(75,797	)		(47,486	)
Total	$	63,432		$	47,549		$	200,879		$	156,017

On July 12, 2022, Tilray acquired the HEXO Convertible Note from HTI and also entered into a strategic alliance with HEXO Corp. (“HEXO”) as discussed in Note 8 (Convertible notes receivable) and Note 13 (Convertible debentures payable). In addition, the Company and HEXO entered into various commercial transaction agreements. On June 22, 2023, the Company completed the HEXO Acquisition as described in Note 7 (Business acquisitions), and thus these commercial arrangements were terminated and HEXO's financial results were consolidated in the current period results.

Included in revenue from Canadian adult-use cannabis is $nil and $1,500 of advisory services revenue for the three and nine months ended February 29, 2024, from the aforementioned HEXO commercial transaction agreements, compared to $8,667 and $24,302 of advisory services revenue in the prior comparative period.

Geographic net revenue:

	*For the three months ended*				*For the nine months ended*
	*February 29,*		*February 28,*		*February 29,*		*February 28,*
	*2024*		*2023*		*2024*		*2023*
North America	$	117,524	$	70,463	$	325,664	$	228,866
EMEA		67,143		71,111		222,139		199,867
Rest of World		3,673		4,015		11,257		14,203
Total	$	188,340	$	145,589	$	559,060	$	442,936

Geographic capital assets:

	*February 29,*		*May 31,*
	*2024*		*2023*
North America	$	473,779	$	319,173
EMEA		101,271		107,131
Rest of World		3,733		3,363
Total	$	578,783	$	429,667

Major customers are defined as customers that are materially significant to the Company’s annual revenues. For the three and nine months ended February 29, 2024 and 2023, there were no major customers representing a material contribution to our quarterly revenues.

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//280/tableOfContent

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-26

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-34

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Note 27 - Subsequent Events

9 Months Ended

Feb. 29, 2024

Subsequent Events [Text Block]

Note 27. Subsequent Events

On April 9, 2024, the Company entered into an agreement to exchange $41,900 principal amount of its APHA 24 Notes for cancellation by issuing up to 25,000,000 shares.

Note 6 - Goodwill - Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Effect of foreign exchange	$ 8,664	$ 7,875
Impairments	(842,431)	(842,431)
Goodwill	2,009,632	2,008,843
Cannabis Segment [Member]
Goodwill, gross	2,640,669	2,640,669
Tilray Pharma [Member]
Goodwill, gross	4,458	4,458
Beverage Alcohol Business [Member]
Goodwill, gross	120,802	120,802
Wellness Business [Member]
Goodwill, gross	$ 77,470	$ 77,470

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

Note 5 - Intangible Assets- Schedule of Estimated Amortization Expense (Details) $ in Thousands	Feb. 29, 2024 USD ($)
2024 (remaining three months)	$ 18,359
2025	73,439
2026	73,439
2027	73,439
2028	73,439
Thereafter	435,139
Total	$ 747,254

Note 2 - Inventory - Schedule of Inventory (Details) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Inventory	$ 244,139	$ 200,551
Beverage Alcohol Inventory [Member]
Inventory	47,606	27,837
Plants [Member]
Inventory	18,623	10,884
Dried Cannabis [Member]
Inventory	102,043	89,801
Cannabis Trim [Member]
Inventory	0	322
Cannabis Derivatives [Member]
Inventory	4,385	9,229
Cannabis Vapes [Member]
Inventory	5,250	1,173
Packaging and Other Inventory Items [Member]
Inventory	21,782	19,997
Tilray Pharma [Member]
Inventory	33,466	30,144
Wellness Inventory [Member]
Inventory	$ 10,984	$ 11,164

Note 26 - Segment Reporting - Geographic Net Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
Net revenue	$ 188,340	$ 145,589	$ 559,060	$ 442,936
North America [Member]
Net revenue	117,524	70,463	325,664	228,866
EMEA [Member]
Net revenue	67,143	71,111	222,139	199,867
Rest of World [Member]
Net revenue	$ 3,673	$ 4,015	$ 11,257	$ 14,203

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

Note 19 - Commitments and Contingencies - Schedule of Commitments (Details) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Total	$ 487,488
Total, 2024	120,974
Total, 2025	71,891
Total, 2026	8,973
Total, 2027	182,835
Total, thereafter	102,815
Material Purchase Obligations [Member]
Purchase obligations, total	49,159
Purchase obligations, 2024	21,587
Purchase obligations, 2025	27,572
Purchase obligations, 2026	0
Purchase obligations, 2027	0
Purchase obligations, thereafter	0
Capital Addition Purchase Commitments [Member]
Purchase obligations, total	822
Purchase obligations, 2024	822
Purchase obligations, 2025	0
Purchase obligations, 2026	0
Purchase obligations, 2027	0
Purchase obligations, thereafter	0
Long-term Debt, Excluding Convertible Debentures [Member]
Debt instrument	178,977	$ 161,707
Debt Instrument, 2024	12,535
Long-term debt repayment	44,319
Debt instrument, 2026	8,973
Debt instrument, 2027	10,335
Debt instrument, thereafter	102,815
Convertible Debentures [Member]
Debt instrument	258,530
Debt Instrument, 2024	86,030
Long-term debt repayment	0
Debt instrument, 2026	0
Debt instrument, 2027	172,500
Debt instrument, thereafter	$ 0

Note 15 - Stockholders' Equity (Tables)

9 Months Ended

Feb. 29, 2024

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	*For the three months ended*				*For the nine months ended*
	*February 29,*		*February 28,*		*February 29,*		*February 28,*
	*2024*		*2023*		*2024*		*2023*
Stock options		$ —		$ 20		$ —		$ 644
RSUs		8,059		9,610		24,517		29,122
Total		$ 8,059		$ 9,630		$ 24,517		$ 29,766

Note 22 - General and Administrative Expenses (Tables)

9 Months Ended

Feb. 29, 2024

Schedule of General and Administrative Expenses [Table Text Block]

	*For the three months ended*					*For the nine months ended*
	*February 29,*		*February 28,*			*February 29,*		*February 28,*
	*2024*		*2023*			*2024*		*2023*
Executive compensation	$	1,585	$	2,754		$	4,757	$	9,359
Office and general		4,190		6,799			20,423		20,011
Salaries and wages		19,588		13,621			52,310		38,407
Stock-based compensation		8,059		9,630			24,517		29,766
Insurance		3,569		3,159			9,917		8,588
Professional fees		656		1,165			4,658		5,385
(Gain) loss on sale of capital assets		23		(15	)		3		(2	)
Travel and accommodation		1,246		1,104			3,727		3,484
Rent		1,024		782			3,457		2,387
Total	$	39,940	$	38,999		$	123,769	$	117,385

Note 9 - Long Term Investments (Tables)

9 Months Ended

Feb. 29, 2024

Debt Securities, Trading, and Equity Securities, FV-NI [Table Text Block]

	*February 29,*		*May 31,*
	*2024*		*2023*
Equity investments measured at fair value	$	2,558	$	2,144
Equity investments under measurement alternative		5,500		5,651
Total	$	8,058	$	7,795

Note 21 - General and Administrative Expenses - Components of General and Administrative Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
Executive compensation	$ 1,585	$ 2,754	$ 4,757	$ 9,359
Office and general	4,190	6,799	20,423	20,011
Salaries and wages	19,588	13,621	52,310	38,407
Share-Based Payment Arrangement, Expense	8,059	9,630	24,517	29,766
Insurance	3,569	3,159	9,917	8,588
Professional fees	656	1,165	4,658	5,385
(Gain) loss on sale of capital assets	23	(15)	3	(2)
Travel and accommodation	1,246	1,104	3,727	3,484
Rent	1,024	782	3,457	2,387
Total	$ 39,940	$ 38,999	$ 123,769	$ 117,385

Note 23 - Restructuring Charges (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
Restructuring Costs	$ 5,178	$ 2,663	$ 8,748	$ 10,727
Cost Optimization [Member] \| Distribution Business [Member]
Restructuring Costs		2,663		10,727
Restructuring and Related Cost, Expected Cost	$ 3		3
Employee Severance [Member] \| Cost Reduction [Member]
Restructuring Costs			475
Employee Severance [Member] \| Cost Optimization [Member] \| Distribution Business [Member]
Restructuring Costs		$ 2,663
Employee Severance [Member] \| HEXO Acquisition [Member]
Restructuring Costs			3,987
Facility Closing [Member] \| CANADA
Restructuring and Related Cost, Incurred Cost				1,512,000
Facility Closing [Member] \| Distribution Business [Member]
Restructuring and Related Cost, Incurred Cost				2,195,000
Facility Closing [Member] \| Cost Optimization [Member] \| Distribution Business [Member]
Restructuring Costs				1,599
Facility Closing [Member] \| Truss Beverage Company [Member]
Restructuring Costs			3,454
One-time Termination Benefits [Member] \| Cost Optimization [Member] \| Distribution Business [Member]
Restructuring Costs			$ 832
Contract Termination [Member] \| Cost Optimization [Member] \| Distribution Business [Member]
Restructuring Costs				$ 2,758

Note 22 - General and Administrative Expenses

9 Months Ended

Feb. 29, 2024

General and Administrative Expenses [Text Block]

Note 22. General and administrative expenses

General and administrative expenses are comprised of:

	*For the three months ended*					*For the nine months ended*
	*February 29,*		*February 28,*			*February 29,*		*February 28,*
	*2024*		*2023*			*2024*		*2023*
Executive compensation	$	1,585	$	2,754		$	4,757	$	9,359
Office and general		4,190		6,799			20,423		20,011
Salaries and wages		19,588		13,621			52,310		38,407
Stock-based compensation		8,059		9,630			24,517		29,766
Insurance		3,569		3,159			9,917		8,588
Professional fees		656		1,165			4,658		5,385
(Gain) loss on sale of capital assets		23		(15	)		3		(2	)
Travel and accommodation		1,246		1,104			3,727		3,484
Rent		1,024		782			3,457		2,387
Total	$	39,940	$	38,999		$	123,769	$	117,385

Included in office and general is $4,440 (C$6,000) of bad debt recoveries on a previously recognized credit loss provision, see Note 19 (Commitments and contingencies), 420 Investments Ltd. Litigation.

Note 25 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Equity investments measured at fair value	$ 2,558	$ 2,144
Contingent consideration	0	(16,218)
Fair Value, Recurring [Member]
Cash and cash equivalents	146,253	206,632
Marketable securities	79,605	241,897
Convertible notes receivable	32,000	103,401
Equity investments measured at fair value	8,058	7,795
Warrant liability	(3,182)	(1,817)
Contingent consideration	(14,000)	(27,107)
Total recurring fair value measurements	165,383	410,233
Fair Value, Recurring [Member] \| APHA 24 [Member]
APHA 24 Convertible debenture	(83,351)	(120,568)
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents	146,253	206,632
Marketable securities	79,605	241,897
Convertible notes receivable	0	0
Equity investments measured at fair value	1,104	1,056
Warrant liability	0	0
Contingent consideration	0	0
Total recurring fair value measurements	226,962	449,585
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member] \| APHA 24 [Member]
APHA 24 Convertible debenture	0	0
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents	0	0
Marketable securities	0	0
Convertible notes receivable	0	0
Equity investments measured at fair value	1,454	1,088
Warrant liability	0	0
Contingent consideration	0	0
Total recurring fair value measurements	1,454	1,088
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member] \| APHA 24 [Member]
APHA 24 Convertible debenture	0	0
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents	0	0
Marketable securities	0	0
Convertible notes receivable	32,000	103,401
Equity investments measured at fair value	5,500	5,651
Warrant liability	(3,182)	(1,817)
Contingent consideration	(14,000)	(27,107)
Total recurring fair value measurements	(63,033)	(40,440)
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member] \| APHA 24 [Member]
APHA 24 Convertible debenture	$ (83,351)	$ (120,568)

Note 5 - Intangible Assets (Tables)

9 Months Ended

Feb. 29, 2024

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	*February 29,*			*May 31,*
	*2024*			*2023*
Customer relationships & distribution channel	$	617,143		$	614,062
Licenses, permits & applications		368,649			366,793
Non-compete agreements		12,422			12,394
Intellectual property, trademarks, knowhow & brands		594,441			583,468
		1,592,655		$	1,576,717
Less: accumulated amortization		(246,706	)		(187,088	)
Less: impairments		(415,844	)		(415,844	)
Total	$	930,105		$	973,785

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

	*Amortization*
2024 (remaining three months)	$	18,359
2025		73,439
2026		73,439
2027		73,439
2028		73,439
Thereafter		435,139
Total	$	747,254

Note 25 - Fair Value Measurements (Tables)

9 Months Ended

Feb. 29, 2024

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

								*February 29,*
	*Level 1*		*Level 2*		*Level 3*			*2024*
Financial assets
Cash and cash equivalents	$	146,253	$	—	$	—		$	146,253
Marketable securities		79,605		—		—			79,605
Convertible notes receivable		—		—		32,000			32,000
Equity investments measured at fair value		1,104		1,454		5,500			8,058
Financial liabilities
Warrant liability		—		—		(3,182	)		(3,182	)
Contingent consideration		—		—		(14,000	)		(14,000	)
APHA 24 Convertible debenture		—		—		(83,351	)		(83,351	)
Total recurring fair value measurements	$	226,962	$	1,454	$	(63,033	)	$	165,383

								*May 31,*
	*Level 1*		*Level 2*		*Level 3*			*2023*
Financial assets
Cash and cash equivalents	$	206,632	$	—	$	—		$	206,632
Marketable Securities		241,897		—		—			241,897
Convertible notes receivable		—		—		103,401			103,401
Equity investments measured at fair value		1,056		1,088		5,651			7,795
Financial liabilities
Warrant liability		—		—		(1,817	)		(1,817	)
Contingent consideration		—		—		(27,107	)		(27,107	)
APHA 24 Convertible debenture		—		—		(120,568	)		(120,568	)
Total recurring fair value measurements	$	449,585	$	1,088	$	(40,440	)	$	410,233

Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

													*APHA 24*
	*Convertible*			*Equity*			*Warrant*			*Contingent*			*Convertible*
	*notes receivable*			*Investments*			*Liability*			*Consideration*			*Debt*
Balance, May 31, 2023	$	103,401		$	5,651		$	(1,817	)	$	(27,107	)	$	(120,568	)
Additions/(Repayments)		—			—			—			(4,181	)		50,710
Redemption		(28,720	)		—			—			760			—
Unrealized gain (loss) on fair value		—			(151	)		(1,365	)		16,528			(13,493	)
Impairments		(42,681	)		—			—			—			—
Balance, February 29, 2024	$	32,000		$	5,500		$	(3,182	)	$	(14,000	)	$	(83,351	)

Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

		*Significant*
	*Valuation*	*unobservable*
Financial asset / financial liability	*technique*	*input*	*Inputs*
APHA Convertible debentures	Black-Scholes	Volatility,	50%
		expected life (in years)	0.3
Warrant liability	Black-Scholes	Volatility,	50%
		expected life (in years)	1.6
Contingent consideration	Discounted cash flows	Discount rate,	11	%
		achievement	95%

Note 5 - Intangible Assets

9 Months Ended

Feb. 29, 2024

Intangible Assets Disclosure [Text Block]

Note 5. Intangible Assets

Intangible assets consisted of the following items:

	*February 29,*			*May 31,*
	*2024*			*2023*
Customer relationships & distribution channel	$	617,143		$	614,062
Licenses, permits & applications		368,649			366,793
Non-compete agreements		12,422			12,394
Intellectual property, trademarks, knowhow & brands		594,441			583,468
		1,592,655		$	1,576,717
Less: accumulated amortization		(246,706	)		(187,088	)
Less: impairments		(415,844	)		(415,844	)
Total	$	930,105		$	973,785

Included in licenses, permits & applications was $182,851 of indefinite-lived intangible assets as of February 29, 2024, compared to $181,093 as of May 31, 2023.

Expected future amortization expense for intangible assets as of February 29, 2024 are as follows:

	*Amortization*
2024 (remaining three months)	$	18,359
2025		73,439
2026		73,439
2027		73,439
2028		73,439
Thereafter		435,139
Total	$	747,254

Note 15 - Stockholders' Equity

9 Months Ended

Feb. 29, 2024

Equity [Text Block]

Note 15. Stockholders' equity

Issued and outstanding

As of February 29, 2024, the Company had 1,198,000,000 common shares and 10,000,000 preferred shares authorized to be issued, with 774,028,053 common shares and nil preferred shares issued and outstanding. Historically, the Company has issued shares of its common stock as consideration for business acquisitions, settlement of convertible notes, settlement of litigation claims, in connection with public offerings and as payment of dividends to non-controlling interests for profit distributions.

During the nine months ended February 29, 2024, the Company issued the following common shares:

39,705,962 shares in connection with the HEXO Acquisition, see Note 7 (Business acquisitions).

865,426 shares to settle a contractual change of control severance obligations in the aggregate amount of $1,500 incurred in connection with the HEXO Acquisition.

18,632,126 shares to settle dividends payable to the non-controlling shareholders of 1974568 Ontario Limited (“Aphria Diamond”).

1,032,616 shares for the settlement of the HTI Convertible Note payable see Note 13 (Convertible debentures payable).

17,148,541 shares to HTI Investments MA LLC pursuant to the terms of a $50.0 million convertible promissory note originally issued by Tilray to HTI on July 12, 2022 and which was settled at maturity as previously disclosed.

1,573,152 shares to settle HEXO-based litigation judgement obtained by MediPharm Labs Inc. in 2022.

	g)	7,000,000 shares to repurchase $20,000 of its TLRY 23 Notes for cancellation.
	h)	27,228,252 shares to repurchase $50,710 of its APHA 24 Notes for cancellation.

4,186,523 shares in connection with the exercise of previously awarded stock-based compensation awards.

The Company maintains stock-based compensation plans as disclosed in our Annual Financial Statements. For the three and nine months ended February 29, 2024, the total stock-based compensation was $ 8,059 and $ 24,517. For the three and nine months ended February 28, 2023, total stock based compensation was $ 9,630 and $ 29,766 respectively.

During the nine months ended February 29, 2024 the Company granted 11,559,549 time-based RSUs, and 7,566,146 performance-based RSUs ( February 28, 2023 - 6,004,995 time-based RSUs and 2,634,744 performance based RSUs). The 7,566,146 performance based RSUs issued during the quarter contains certain performance conditions that will only be set a future date, and therefore for accounting purposes the grant date has not been met. The Company's total stock-based compensation expense recognized is as follows:

	*For the three months ended*				*For the nine months ended*
	*February 29,*		*February 28,*		*February 29,*		*February 28,*
	*2024*		*2023*		*2024*		*2023*
Stock options		$ —		$ 20		$ —		$ 644
RSUs		8,059		9,610		24,517		29,122
Total		$ 8,059		$ 9,630		$ 24,517		$ 29,766

The entire disclosure for equity.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Note 7 - Business Acquisitions

9 Months Ended

Feb. 29, 2024

Business Combination Disclosure [Text Block]

Note 7. Business acquisitions

Acquisition of Montauk Brewing Company, Inc.

On November 7, 2022, Tilray acquired Montauk Brewing Company, Inc. (“Montauk”), a leading craft brewer based in Montauk, New York, which expanded our distribution network with a strong brand in the tri-state region of the U.S. In consideration for the acquisition of Montauk, and after giving effect to post-closing adjustments, the Company paid an aggregate purchase price equal to $35,123, which was comprised of $ 28,701 in cash and the remainder through the issuance of 1,708,521 shares of Tilray's common stock (having a value of $6,422 at closing). In the event that Montauk achieves certain volume and/or EBITDA targets on or before December 31, 2025, the stockholders of Montauk shall be eligible to receive additional contingent cash consideration of up to $18,000. The Company determined that the closing date fair value of this contingent consideration was $10,245 based on the inputs disclosed in Note 25 (Fair value measurements).

The table below summarizes the fair value of the assets acquired and liabilities assumed at the acquisition date.

	*Amount*
Consideration
Cash	$	28,701
Shares		6,422
Contingent consideration		10,245
Net assets acquired
Current assets
Cash and cash equivalents		1,983
Accounts receivable		1,116
Prepaids and other current assets		467
Inventory		1,570
Long-term assets
Capital assets		420
Customer relationships (15 years)		18,540
Intellectual property, trademarks & brands (15 years)		13,650
Goodwill		17,803
Total assets		55,549
Current liabilities
Accounts payable and accrued liabilities		1,580
Long-term liabilities
Deferred tax liability		4,851
Other liabilities		3,750
Total liabilities		10,181
Total net assets acquired	$	45,368

In the event that the Montauk acquisition had occurred on June 1, 2022, the Company would have had additional net revenue of approximately $3,100 and $12,100 for the three and nine months ended February 28, 2023, respectively, and its consolidated net loss and comprehensive net loss would have increased by approximately $600 and $1,100 for the three and nine months ended February 28, 2023, respectively, primarily as a result of amortization of the intangible assets acquired. This unaudited pro forma financial information does not reflect the realization of any expected ongoing synergies relating to the integration of Montauk.

Acquisition of HEXO Corp.

On June 22, 2023, Tilray acquired HEXO, a cannabis company in Canada (the “HEXO Acquisition”) for the purpose of expanding the Company’s revenue base, production capabilities around certain form factors and growth opportunities with the Redecan brand. In consideration for the HEXO Acquisition, the Company paid a total purchase price equivalent of $93,882, which consisted of stock consideration of $63,927, settlement of convertible notes receivable of $28,720, the fair value of HEXO stock-based compensation of $1,188 and the assumption of warrants of $47. In connection with the HEXO Acquisition, each outstanding HEXO common share was exchanged for 0.4352 of a share of Tilray common stock and each outstanding HEXO preferred share was exchanged for 0.7805 of a share of Tilray common stock. In the aggregate, the Company issued 39,705,962 shares of Tilray common stock, at a share price of $1.61 per share, in connection with the HEXO Acquisition. The Company intends to sell HEXO's Kirkland lake property and the Quebec cultivation facility, and has recorded the value of the associated capital assets as assets held for sale, see Note 3 (Capital assets).

The Company is in the process of assessing the fair value of the net assets acquired and, as a result, the fair value may be subject to adjustments pending completion of final valuations and post-closing adjustments. The table below summarizes the preliminary estimated fair value of the assets acquired and the liabilities assumed for the HEXO Acquisition at the acquisition date as follows:

	*Amount*
Consideration
Shares	$	63,927
Settlement of convertible notes receivable		28,720
Warrants assumed		47
Estimated fair value of HEXO stock-based compensation		1,188
Net assets acquired
Current assets
Cash and cash equivalents		14,634
Restricted cash		1,656
Accounts receivable		7,855
Asset held for sale		755
Prepaids and other current assets		2,709
Inventory		25,947
Long-term assets
Prepaid expenses		8,384
Capital assets		70,634
Intellectual property, trademarks & brands (15 years)		2,680
Interest in equity investee		3,145
Total assets		138,399
Current liabilities
Accounts payable and accrued liabilities		44,517
Total liabilities		44,517
Total net assets acquired	$	93,882

Included in accounts payable and accrued liabilities was $12,253 of litigation settlement accruals as of June 22, 2023.

In the event the HEXO Acquisition had occurred on June 1, 2022, the Company would have had, on an unaudited proforma basis, additional net revenue of approximately $nil and $7,000 for the three and nine months ended February 29, 2024, respectively, and $15,000 and $55,000 for the three and nine months ended February 28, 2023, respectively, and its net loss and comprehensive net loss would have increased by approximately $nil and $1,800 for the three and nine months period ended February 29, 2024, respectively, and $25,000 and $85,000 for the three and nine months period ended February 28, 2023, respectively. This unaudited pro forma financial information does not reflect the realization of any expected ongoing synergies relating to the integration of HEXO.

Acquisition of Truss Beverage Co.

On August 3, 2023, Tilray acquired the remaining 57.5% equity interest in Truss Beverage Co. ("Truss"), a cannabis beverage company, from Molson Coors Canada ("Molson"). This purchase represents the equity portion of Truss that had not been previously acquired as part of the HEXO Acquisition. The consideration paid by Tilray consisted of $74 (CAD$100) in cash and contingent consideration fair valued at $4,181. During the three months ended February 29, 2024, the contingent consideration liability was settled in exchange for a final payment equal to $760 with the resultant gain of $3,683 recorded in change in fair value of contingent consideration, offset by $262 of foreign exchange. Tilray initially planned to divest Truss' assets and recorded the value of the associated capital assets and lease obligations as an asset held for sale. During the quarter ended November 30, 2023, due to a change in circumstance in the Company's ability to sell these assets, they were subsequently reclassified as capital assets as the Company has made alternative plans for their utilization. The asset was then remeasured at the lower of its carrying amount before being classified as held for sale less the amortization that would have occurred and the fair value on the date the decision not to proceed with a sale was made. Changes in the carrying amount were recorded in the consolidated statement of net loss and comprehensive loss as amortization in cost of goods sold.

The Company is in the process of assessing the fair value of the net assets acquired and, as a result, the fair value of the net assets acquired may be subject to adjustments pending completion of final valuations and post-closing adjustments. The table below summarizes preliminary estimated fair value of the assets acquired and the liabilities assumed at the acquisition date as follows:

	*Amount*
Consideration
Cash consideration	$	74
Investment in equity investees		3,145
Contingent consideration		4,181
Net assets acquired
Current assets
Cash and cash equivalents		6,739
Accounts receivable		1,038
Prepaids and other current assets		78
Inventory		2,573
Asset held for sale		2,960
Long-term assets
Intangible assets		296
Total assets		13,684
Current liabilities
Accounts payable and accrued liabilities		5,408
Other liabilities		876
Total liabilities		6,284
Total net assets acquired		7,400

In the event that the Truss acquisition had occurred on June 1, 2022 the Company would have had, on an unaudited proforma basis, additional net revenue of approximately $nil and $3,000 for the three and nine months ended February 29, 2024, respectively, and $4,600 and $10,900 for the three and nine months period ended February 28, 2023, respectively, and its consolidated net loss and comprehensive net loss would have increased by approximately $nil and $700 for the three and nine months ended February 29, 2024, respectively, and $600 and $1,800 for the three and nine months period ended February 28, 2023, respectively. This unaudited pro forma financial information does not reflect the realization of any expected ongoing synergies relating to the integration of Truss.

Acquisition of Craft Beverage Business Portfolio

On September 29, 2023, Tilray acquired a portfolio of craft brands, assets and businesses comprising eight beer and beverage brands from Anheuser-Busch Companies, LLC, ("AB") including breweries and brewpubs associated with them (the “Craft Acquisition”). The acquired businesses/brands include Shock Top, Breckenridge Brewery, Blue Point Brewing Company, 10 Barrel Brewing Company, Redhook Brewery, Widmer Brothers Brewing, Square Mile Cider Company, and HiBall Energy. The Company paid a total purchase price equivalent of $83,658 in cash, net of a preliminary working capital adjustment at closing of $1,342, which is subject to a final working capital adjustment. As described in Note 12 (Long-term debt), $20,000 was borrowed under the ABC Group Delayed Draw Term Loan Agreement to fund part of the purchase price paid for the Craft Acquisition.

The Company is in the process of assessing the fair value of the net assets acquired and, as a result, the fair value may be subject to adjustments pending completion of final valuations and post-closing adjustments. The table below summarizes the preliminary estimated fair value of the assets acquired and the liabilities assumed for the Craft Acquisition at the effective acquisition date as follows:

	*Amount*
Consideration
Cash consideration	$	83,658
Net assets acquired
Current assets
Cash and cash equivalents		77
Inventory		22,493
Prepaids and other current assets		573
Long-term assets
Capital assets		62,614
Finance lease, right-of-use assets		45,496
Operating lease, right-of-use assets		7,677
Other assets		108
Total assets		139,038
Current liabilities
Accounts payable and accrued liabilities		2,206
Current portion of finance lease liabilities		1,031
Current portion of operating lease liabilities		1,408
Long - term liabilities
Finance lease liabilities		44,465
Operating lease liabilities		6,270
Total liabilities		55,380
Total net assets acquired		83,658

In the event that the Craft Acquisition had occurred on June 1, 2022, the Company would have had, on an unaudited proforma basis, additional revenue of approximately $nil and $55,000 for the three and nine months ended February 29, 2024, respectively, and $33,000 and $118,000 for the three and nine months period ended February 28, 2023, respectively, and its net loss and comprehensive net loss would have increased by approximately $nil and $5,000 for the three and nine months ended February 29, 2024, respectively, and $3,500 and $4,400 for the three and nine months period ended February 28, 2023, respectively. This unaudited pro forma financial information does not reflect the realization of any expected ongoing synergies relating to the integration of the Craft Acquisition.

Note 13 - Convertible Debentures Payable - Net Carrying Amount of Convertible Debentures (Details) - USD ($) $ in Thousands			3 Months Ended	9 Months Ended		12 Months Ended
	Oct. 02, 2023	Sep. 12, 2023	Feb. 29, 2024	Feb. 29, 2024	Feb. 28, 2023	May 31, 2023	May 30, 2023	Jul. 12, 2022	Apr. 01, 2019
Deduct - current portion			$ 83,351	$ 83,351		$ 174,378
Total convertible debentures payable, non current portion			126,587	126,587		221,044
Debt settlement				(107,330)	$ 0
HT Investments MA LLC Note [Member]
Carrying amount of long-term debt			0	0		47,834
Debt instrument			0	0		47,834
Carrying amount of long-term debt			$ 0	$ 0		47,834
Contractual debenture						50,000		$ 50,000
Unamortized discount						(2,166)
Convertible debentures						$ 47,834
Rate			4.00%	4.00%		4.00%		4.00%
TLRY 27 [Member]
Carrying amount of long-term debt			$ 126,587	$ 126,587		$ 100,476
Debt instrument			126,587	126,587		100,476
Carrying amount of long-term debt			126,587	126,587		100,476
Contractual debenture			172,500	172,500		150,000	$ 172,500
Unamortized discount			(45,913)	(45,913)		(49,524)
Convertible debentures			$ 126,587	$ 126,587		$ 100,476
Rate			5.20%	5.20%		5.20%	5.20%
APHA 24 [Member]
Carrying amount of long-term debt			$ 83,351	$ 83,351		$ 120,568
Debt instrument			83,351	83,351		120,568
Carrying amount of long-term debt			83,351	83,351		120,568
Deduct - current portion			86,030	86,030		136,740
Contractual debenture			350,000	350,000		350,000			$ 350,000
Convertible debentures			$ 83,351	$ 83,351		$ 120,568
Rate			5.25%	5.25%		5.25%			5.25%
Debt settlement			$ (263,970)			$ (213,260)
Fair value adjustment			(2,679)			(16,172)
TLRY 23 [Member]
Carrying amount of long-term debt			0	$ 0		126,544
Debt instrument			0	0		126,544
Carrying amount of long-term debt			0	0		126,544
Contractual debenture			0	0		277,856
Unamortized discount			0	0		(786)
Convertible debentures			$ 0	$ 0		$ 126,544
Rate			5.00%	5.00%		5.00%
Debt settlement	$ (107,330)	$ (610)	$ 0			$ (150,526)
Convertible Debentures [Member]
Carrying amount of long-term debt			209,938	$ 209,938		395,422
Debt instrument			209,938	209,938		395,422
Carrying amount of long-term debt			$ 209,938	$ 209,938		$ 395,422

Note 25 - Fair Value Measurements - Inputs Used to Recognize Unrealized Gain (Loss) on Fair Value (Details) - Minimum [Member]	Feb. 29, 2024 yr
Valuation Technique, Option Pricing Model [Member] \| Measurement Input, Price Volatility [Member]
Debt instrument, measurement input	0.50
Warrant liability, measurement input	0.50
Valuation Technique, Option Pricing Model [Member] \| Measurement Input, Expected Term [Member]
Debt instrument, measurement input	0.3
Warrant liability, measurement input	1.6
Valuation Technique, Discounted Cash Flow [Member] \| Measurement Input, Discount Rate [Member]
Contingent consideration, measurement input	0.11
Valuation Technique, Discounted Cash Flow [Member] \| Measurement Input, Conversion Rate [Member]
Contingent consideration, measurement input	0.95

Note 12 - Long-term Debt - Net Carrying Amount of Long-term Debt Instruments (Details) (Parentheticals) € in Thousands, $ in Thousands, $ in Thousands	9 Months Ended			12 Months Ended
	Feb. 29, 2024 USD ($)	Feb. 29, 2024 CAD ($)	Feb. 29, 2024 EUR (€)	May 31, 2023 USD ($)	May 31, 2023 CAD ($)	May 31, 2023 EUR (€)	Feb. 29, 2024 CAD ($)	Feb. 29, 2024 EUR (€)	May 31, 2023 CAD ($)	May 31, 2023 EUR (€)
Credit Facility Due in November 2025 [Member]
Face amount							$ 66,000		$ 66,000
Term (Year)	3 years	3 years	3 years	3 years	3 years	3 years
Amortization period (Year)	10 years	10 years	10 years	10 years	10 years	10 years
Maturity	Nov. 30, 2025	Nov. 30, 2025	Nov. 30, 2025	Nov. 30, 2025	Nov. 30, 2025	Nov. 30, 2025
Term Loan Due in July 2033 [Member]
Face amount							25,000		25,000
Term (Year)	5 years	5 years	5 years	5 years	5 years	5 years
Amortization period (Year)	15 years	15 years	15 years	15 years	15 years	15 years
Maturity	Jul. 31, 2033	Jul. 31, 2033	Jul. 31, 2033	Jul. 31, 2033	Jul. 31, 2033	Jul. 31, 2033
Periodic payment		$ 181			$ 181
Term Loan Due in July 2033 [Member] \| Prime Rate [Member]
Variable rate	1.00%	1.00%	1.00%	1.00%	1.00%	1.00%
Term Loan Due in July 2033 Two [Member]
Face amount							25,000		25,000
Term (Year)	5 years	5 years	5 years	5 years	5 years	5 years
Amortization period (Year)	15 years	15 years	15 years	15 years	15 years	15 years
Maturity	Jul. 31, 2033	Jul. 31, 2033	Jul. 31, 2033	Jul. 31, 2033	Jul. 31, 2033	Jul. 31, 2033
Variable rate	1.00%	1.00%	1.00%	1.00%	1.00%	1.00%
Periodic payment		$ 196			$ 196
Term Loan Due in August 2026 [Member]
Face amount							1,250		1,250
Term (Year)	5 years	5 years	5 years	5 years	5 years	5 years
Amortization period (Year)	10 years	10 years	10 years	10 years	10 years	10 years
Maturity	Aug. 31, 2026	Aug. 31, 2026	Aug. 31, 2026	Aug. 31, 2026	Aug. 31, 2026	Aug. 31, 2026
Periodic payment		$ 12			$ 12
Term Loan Due in August 2026 [Member] \| Prime Rate [Member]
Variable rate	1.50%	1.50%	1.50%	1.50%	1.50%	1.50%
Mortgage Payable Due in August 2026 [Member]
Face amount							$ 3,750		$ 3,750
Term (Year)	5 years	5 years	5 years	5 years	5 years	5 years
Amortization period (Year)	20 years	20 years	20 years	20 years	20 years	20 years
Maturity	Aug. 31, 2026	Aug. 31, 2026	Aug. 31, 2026	Aug. 31, 2026	Aug. 31, 2026	Aug. 31, 2026
Periodic payment		$ 23			$ 23
Mortgage Payable Due in August 2026 [Member] \| Prime Rate [Member]
Variable rate	1.50%	1.50%	1.50%	1.50%	1.50%	1.50%
Term Loan Due in December 2023, One [Member]
Face amount \| €								€ 5,000		€ 5,000
Term (Year)	5 years	5 years	5 years	5 years	5 years	5 years
Maturity	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023
Periodic payment \| €			€ 250			€ 250
Term Loan Due in December 2023, One [Member] \| Euro Interbank Offered Rate [Member]
Variable rate	2.15%	2.15%	2.15%	2.15%	2.15%	2.15%
Term Loan Due in December 2023, Two [Member]
Face amount \| €								€ 1,200		€ 1,200
Term (Year)	1 year	1 year	1 year	1 year	1 year	1 year
Maturity	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023
Periodic payment \| €			€ 100			€ 100
Rate	4.26%			4.26%			4.26%	4.26%	4.26%	4.26%
Term Loan Due in April 2025 [Member]
Face amount \| €								€ 1,500		€ 1,500
Term (Year)	5 years	5 years	5 years	5 years	5 years	5 years
Maturity	Apr. 30, 2025	Apr. 30, 2025	Apr. 30, 2025	Apr. 30, 2025	Apr. 30, 2025	Apr. 30, 2025
Periodic payment \| €			€ 94			€ 94
Rate	2.00%			2.00%			2.00%	2.00%	2.00%	2.00%
Term Loan Due in August 2028 [Member]
Face amount	$ 3,500			$ 3,500
Term (Year)	5 years	5 years	5 years	5 years	5 years	5 years
Maturity	Aug. 31, 2028	Aug. 31, 2028	Aug. 31, 2028	Aug. 31, 2028	Aug. 31, 2028	Aug. 31, 2028
Periodic payment \| €			€ 52			€ 52
Rate	4.59%			4.59%			4.59%	4.59%	4.59%	4.59%
Mortgage Payable Due in October 2030 [Member]
Face amount	$ 22,635			$ 22,635
Term (Year)	10 years	10 years	10 years	10 years	10 years	10 years
Maturity	Oct. 31, 2030	Oct. 31, 2030	Oct. 31, 2030	Oct. 31, 2030	Oct. 31, 2030	Oct. 31, 2030
Periodic payment	$ 57			$ 57
Mortgage Payable Due in October 2030 [Member] \| Euro Interbank Offered Rate [Member]
Variable rate	1.50%	1.50%	1.50%	1.50%	1.50%	1.50%
Term Loan Due in June 2028 [Member]
Face amount	$ 90,000			$ 90,000
Term (Year)	5 years	5 years	5 years	5 years	5 years	5 years
Maturity	Jun. 30, 2028	Jun. 30, 2028	Jun. 30, 2028	Jun. 30, 2028	Jun. 30, 2028	Jun. 30, 2028
Term Loan Due in June 2028 [Member] \| Minimum [Member]
Periodic payment	$ 875			$ 875
Term Loan Due in June 2028 [Member] \| Maximum [Member]
Periodic payment	$ 1,750			$ 1,750

Note 26 - Segment Reporting (Details Textual) $ in Thousands	3 Months Ended		6 Months Ended	9 Months Ended
	Feb. 29, 2024 USD ($)	Feb. 28, 2023 USD ($)	Feb. 29, 2024	Feb. 29, 2024 USD ($)	Feb. 28, 2023 USD ($)
Number of Reportable Segments			4
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| Major Customers [Member]
Number Of Major Customers	0	0		0	0
Advisory Services Agreement With HEXO [Member] \| Advisory Services Revenue [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 0	$ 8,667		$ 1,500	$ 24,302

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

Note 26 - Segment Reporting (Tables)

9 Months Ended

Feb. 29, 2024

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	*For the three months ended*					*For the nine months ended*
	*February 29,*		*February 28,*			*February 29,*		*February 28,*
	*2024*		*2023*			*2024*		*2023*
Beverage alcohol
Net beverage alcohol revenue	$	54,688	$	20,640		$	125,355	$	62,689
Beverage alcohol costs		35,836		10,663			77,615		32,932
Beverage alcohol gross profit		18,852		9,977			47,740		29,757
Cannabis
Net cannabis revenue		63,432		47,549			200,879		156,017
Cannabis costs		42,518		80,362			139,507		137,800
Cannabis gross profit (loss)		20,914		(32,813	)		61,372		18,217
Distribution
Distribution revenue		56,794		65,385			193,174		186,158
Distribution costs		51,231		57,964			172,846		165,443
Distribution gross profit		5,563		7,421			20,328		20,715
Wellness
Wellness revenue		13,426		12,015			39,652		38,072
Wellness costs		9,359		8,299			28,091		26,964
Wellness gross profit	$	4,067	$	3,716		$	11,561	$	11,108

	*For the three months ended*						*For the nine months ended*
	*February 29,*			*February 28,*			*February 29,*			*February 28,*
	*2024*			*2023*			*2024*			*2023*
Revenue from Canadian medical cannabis	$	6,363		$	6,035		$	18,793		$	18,920
Revenue from Canadian adult-use cannabis		62,107			45,318			205,350			156,063
Revenue from wholesale cannabis		2,764			58			12,348			686
Revenue from international cannabis		14,002			9,707			40,185			27,834
Less excise taxes		(21,804	)		(13,569	)		(75,797	)		(47,486	)
Total	$	63,432		$	47,549		$	200,879		$	156,017

Revenue from External Customers by Geographic Areas [Table Text Block]

	*For the three months ended*				*For the nine months ended*
	*February 29,*		*February 28,*		*February 29,*		*February 28,*
	*2024*		*2023*		*2024*		*2023*
North America	$	117,524	$	70,463	$	325,664	$	228,866
EMEA		67,143		71,111		222,139		199,867
Rest of World		3,673		4,015		11,257		14,203
Total	$	188,340	$	145,589	$	559,060	$	442,936

Long-Lived Assets by Geographic Areas [Table Text Block]

	*February 29,*		*May 31,*
	*2024*		*2023*
North America	$	473,779	$	319,173
EMEA		101,271		107,131
Rest of World		3,733		3,363
Total	$	578,783	$	429,667

Significant Accounting Policies (Policies)	9 Months Ended
Significant Accounting Policies (Policies)	Feb. 29, 2024
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Basis of consolidation Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of all subsidiaries are included in the condensed interim consolidated financial statements from the date that control commences until the date that control ceases. All intercompany balances and transactions have been eliminated on consolidation. A complete list of our subsidiaries that existed as of our most recent fiscal year end is included in the Annual Report, except for the entities acquired within Note 7 (Business acquisitions) during the nine months ended February 29, 2024.
Marketable Securities, Policy [Policy Text Block]	Marketable securities We classify term deposits and other investments that have maturities of greater than three months but less than one year as marketable securities. The fair value of marketable securities is based on quoted market prices for publicly traded securities. Marketable securities are carried at fair value with changes in fair value recorded in the statement of net loss and comprehensive loss within the line “Non-operating income (expense), net”.
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted cash We classify cash that is legally or contractually restricted as to withdrawal or usage as restricted cash. As of February 29, 2024, and May 31, 2023, the Company reported $nil restricted cash. During the six months ended November 31, 2023, the Company acquired $1,656 of restricted cash related to letters of credit and collateral from the acquisition of HEXO Corp. as described in Note 7 (Business acquisitions). During the three months ended February 29, 2024, all of the restricted cash was released and transferred to cash and cash equivalents.
Assets Held-for-Sale, Policy [Policy Text Block]	Assets held for sale We classify capital assets that are available for immediate sale in their present condition, which the Company has approved the action or plan to sell, and the sales is probable within one year, as assets held for sale. As of February 29, 2024, the Company reported $28,638 assets held for sale related to the Kirkland lake property, the Quebec cultivation facility and the Fort Collins facility, see Note 3 (Capital assets). Assets held for sale are to be measured at the lower of carrying amount and the fair value less costs to sell. Disposition of assets held for sale are recorded in the statement of net loss and comprehensive loss, within the line, “Non-operating income (expense)”. When there are changes in circumstances that were previously considered unlikely to occur, and it is decided not to proceed with a sale, an asset that was previously classified as assets held for sale is reclassified as held and used. The asset is then remeasured at the lower of its carrying amount before being classified as held for sale less the amortization that would have occurred and the fair value on the date the decision not to proceed with a sale was made. Changes in the carrying amount are recorded in the statement of net loss and comprehensive loss.
Investment, Policy [Policy Text Block]	Long-term investments Investments in equity securities of entities over which the Company does not have a controlling financial interest or significant influence are classified as an equity investment and accounted for at fair value. Equity investments without readily determinable fair values are measured at cost with adjustments for observable changes in price or impairments (referred to as the “measurement alternative”). In applying the measurement alternative, the Company performs a qualitative assessment on a quarterly basis and recognizes an impairment if there are sufficient indicators that the fair value of an individual equity investment is less than its carrying value. Changes in value are recorded in the statement of net loss and comprehensive loss, within the line, “Non-operating income (expense), net”. Investments in entities over which the Company does not have a controlling financial interest but has significant influence, are accounted for using the equity method, with the Company’s share of earnings or losses reported in earnings or losses from equity method investments on the consolidated statements of loss and comprehensive loss. Equity method investments are recorded at cost, adjusted for the Company’s share of undistributed earnings or losses, and impairment, if any, within “Interest in equity investees” on the balance sheets. The Company assesses investments in equity method investments when events or circumstances indicate that the carrying amount of the investment may be impaired. If it is determined that the current fair value of an equity method investment is less than the carrying value of the investment, the Company will assess if the shortfall is other than temporary (OTTI). Evidence of a loss in value might include, but would not necessarily be limited to, the absence of an ability to recover the carrying amount of the investment or inability of the equity investee to sustain an earnings capacity that would justify the carrying amount of the investment. Once a determination is made that an OTTI exists, the investment is written down to its fair value in accordance with ASC 820 Fair Value Measurement at the reporting date, which establishes a new cost basis.
Financing Receivable [Policy Text Block]	Convertible notes receivable Convertible notes receivable includes various investments in which the Company has the right, or potential right to convert the indenture into common stock of the investee and are classified as available-for-sale and are recorded at fair value. Unrealized gains and losses during the year, net of the related tax effect, are excluded from income and reflected in other comprehensive income (loss), and the cumulative effect is reported as a separate component of shareholders' equity until realized. We use judgement to assess convertible notes receivables for impairment at each measurement date. Convertible notes receivables are impaired when a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the consolidated statements of loss and comprehensive loss and a new cost basis for the investment is established. We also evaluate whether there is a plan to sell the security, or it is more likely than not that we will be required to sell the security before recovery. If neither of the conditions exist, then only the portion of the impairment loss attributable to credit loss is recorded in the statements of loss and the remaining amount is recorded in other comprehensive income (loss).
Revenue [Policy Text Block]	Revenue Revenue is recognized when the control of the promised goods or services, through performance obligation, is transferred or provided to the customer in an amount that reflects the consideration we expect to be entitled to in exchange for the performance obligations. Excise taxes remitted to tax authorities are government-imposed excise taxes on cannabis and beer. Excise taxes are recorded as a reduction of sales in net revenue in the consolidated statements of loss and comprehensive loss and recognized as a current liability within accounts payable and accrued liabilities on the consolidated balance sheets, with the liability subsequently reduced when the taxes are remitted to the tax authority. In addition, amounts disclosed as net revenue are net of excise taxes, sales tax, duty tax, allowances, discounts and rebates. In determining the transaction price for the sale of goods or services, the Company considers the effects of variable consideration and the existence of significant financing components, if any. We may enter into certain contracts for the sale of goods or services, which provide customers with rights of return, volume discounts, bonuses for volume/quality achievement, and/or sales allowances. In addition, the Company may provide in certain circumstances, a retrospective price reduction to a customer based primarily on inventory movement. The inclusion of these items may give rise to variable consideration. The Company uses the expected value method to estimate the variable consideration because this method provides the most accurate estimation of the amount of variable consideration to which the Company will be entitled. The Company uses historical evidence, current information and forecasts to estimate the variable consideration. The Company reduces revenue and recognizes a contract liability, recorded in accounts receivable, net, equal to the amount expected to be refunded to the customer in the form of a future rebate or credit for a retrospective price reduction, representing its obligation to return the customer’s consideration. The estimate is updated at each reporting period date. On July 12, 2022, the Company and HEXO Corp. ("HEXO") entered into various commercial transaction agreements, as described in Note 26 (Segment reporting), which included an advisory services arrangement. The fees associated with the advisory services arrangement were recognized as revenue when such services were provided to HEXO. Any payments that were received for such services in advance of performance were recognized as a contract liability. On June 22, 2023, the Company completed the acquisition of HEXO, as described in Note 7 (Business acquisitions), simultaneously terminating the advisory services arrangement and other commercial transactions.
Transaction Costs Policy [Policy Text Block]	Transaction (income) costs The Company expenses costs net of any gains directly attributable to business acquisitions and classifies these items as transaction (income) costs. These items include among other things, legal fees to complete the acquisition, financial advisor and due diligence costs, and transaction related compensation. These items are recognized as incurred.
Earnings Per Share, Policy [Policy Text Block]	Earnings (loss) per share Basic earnings (loss) per share is computed by dividing reported net income (loss) attributable to stockholders of Tilray Brands, Inc. by the weighted average number of common shares outstanding during the year. Diluted earnings (loss) per share is computed by dividing reported net income (loss) attributable to stockholders of Tilray Brands, Inc. by the sum of the weighted average number of common shares and the number of dilutive potential common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options, warrants, and RSUs and the incremental shares issuable upon conversion of the convertible debentures and similar instruments. Shares of common stock outstanding under the share lending arrangement entered into in conjunction with the TLRY 27 Notes, see Note 13 (Convertible debentures payable) are excluded from the calculation of basic and diluted earnings per share because the borrower of the shares is required under the share lending arrangement to refund any dividends paid on the shares lent. In computing diluted earnings (loss) per share, common share equivalents are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. For the three and nine months ended February 29, 2024 and February 28, 2023, the dilutive potential common share equivalents outstanding consisted of the following: 20,652,315 and 16,431,876 common shares from RSUs, 5,744,302 and 4,660,046 common shares from share options, 6,209,000 and 6,209,000 common shares for warrants and 72,653,364 and 36,388,651 common shares for convertible debentures, respectively.
New Accounting Pronouncements, Policy [Policy Text Block]	New accounting pronouncements not* yet adopted* In August 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-05, Business Combination - Joint Venture Formations (Subtopic 805-60) Recognition and Initial Measurement (“ASU 2023-05”), which is intended to address the accounting for contributions made to a joint venture. ASU 2023-05 is effective for the Company beginning June 1, 2026. This update will be applied prospectively on or after the effective date of the amendments. The Company is currently evaluating the effect of adopting this ASU. In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative, which amends the disclosure or presentation requirements related to various subtopics in the FASB Accounting Standards Codification (the “Codification”). The effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. If by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective for any entity. The Company is currently evaluating the effect of adopting this ASU. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments’ significant expenses on an interim and annual basis. ASU 2023-07 is effective for the Company beginning the year ended May 31, 2025. The Company is currently evaluating the effect of adopting this ASU. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) Improvements to Income Tax Disclosures, which requires public entities to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis. ASU 2023-09 is effective for the Company beginning the year ended June 01, 2024. The Company is currently evaluating the effect of adopting this ASU. New accounting pronouncements recently adopted In October 2021, the FASB issued ASU 2021-08, Business Combinations (Subtopic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency. The Company adopted the ASU 2021-08 beginning June 1, 2023, however, it did not have any impact on our condensed interim consolidated financial statements.

Note 25 - Fair Value Measurements (Details Textual) $ in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2024 USD ($)	Feb. 29, 2024 CAD ($)	Feb. 29, 2024 USD ($)	May 31, 2023 USD ($)
SweetWater, Montauk, and Truss [Member] \| Contingent Consideration [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) From Foreign Exchange			$ (13,493)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)			$ (16,218)
SweetWater, Montauk, and Truss [Member] \| Measurement Input, Discount Rate [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.11		0.11
SweetWater, Montauk, and Truss [Member] \| Measurement Input, Probability of Achievement [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.95		0.95
Acquisition of Montauk Brewing Company, Inc. [Member] \| Contingent Consideration [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)			$ 3,111
Truss Beverage Company [Member] \| Contingent Consideration [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) From Foreign Exchange	$ 760	$ 1,041
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)	4,181
Long-term Debt, Excluding Convertible Debentures [Member]
Long-Term Debt, Percentage Bearing Fixed Interest, Amount	3,846		3,846	$ 3,280
Convertible Debt [Member]
Convertible Debt	$ 258,530		$ 258,530	$ 464,070

Note 3 - Capital Assets

9 Months Ended

Feb. 29, 2024

Property, Plant and Equipment Disclosure [Text Block]

Note 3. Capital assets

Capital assets consisted of the following:

	*February 29,*			*May 31,*
	*2024*			*2023*
Land	$	45,681		$	30,635
Production facility		388,234			344,627
Equipment		253,422			185,422
Leasehold improvement		9,379			7,753
Finance lease, right-of-use assets		56,225			—
Construction in progress		10,907			8,048
	$	763,848		$	576,485
Less: accumulated amortization		(185,065	)		(146,818	)
Total	$	578,783		$	429,667

Assets held for sale consisted of the following:

	February 29,		May 31,
	2024		2023
Land	$	1,380	$	—
Production facility		20,821		—
Equipment		6,437		—
	$	28,638	$	—

On June 22, 2023, the Company acquired HEXO and recognized the Kirkland lake property as held for sale on the acquisition date, see Note 7 (Business combinations). It is expected that the sale of the property will close during the fiscal year ended May 31, 2024.

During the three months ended February 29, 2024, the Company classified its Quebec cultivation facility and the Fort Collins extraction facility as held for sale. Through the assessment of facility capacity utilization, it was determined that these facilities would be exited and held for sale. It is expected that the sale of these assets will be completed within twelve months from the period ended February 29, 2024.

Note 24 - Non-operating Income (Expense) (Details Textual) - USD ($) $ in Thousands	3 Months Ended					9 Months Ended
	Feb. 29, 2024	Nov. 30, 2023	Aug. 31, 2023	Feb. 28, 2023	Aug. 31, 2022	Feb. 29, 2024	Feb. 28, 2023
Other Nonoperating Gains (Losses)	$ (8,245)			$ (1,370)		$ (9,427)	$ (7,545)
Stock Issued During Period, Value, Settlement of Convertible Securities	2,313	$ 2,313	$ 50,000
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	2,458		$ 7,891		$ 8,561
Cannfections Group Inc. [Member]
Equity Securities, FV-NI, Unrealized Gain (Loss)	$ (4,638)

Note 20 - Net Revenue (Details Textual)	9 Months Ended
Note 20 - Net Revenue (Details Textual)	Feb. 29, 2024
Number of Operating Segments	4

Note 2 - Inventory (Tables)

9 Months Ended

Feb. 29, 2024

Schedule of Inventory, Current [Table Text Block]

	*February 29,*		*May 31,*
	*2024*		*2023*
Beverage alcohol inventory	$	47,606	$	27,837
Plants		18,623		10,884
Dried cannabis		102,043		89,801
Cannabis trim		—		322
Cannabis derivatives		4,385		9,229
Cannabis vapes		5,250		1,173
Packaging and other inventory items		21,782		19,997
Distribution inventory		33,466		30,144
Wellness inventory		10,984		11,164
Total	$	244,139	$	200,551

Note 16 - Accumulated Other Comprehensive Income (Loss) - Components of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Feb. 29, 2024	Nov. 30, 2023	Aug. 31, 2023	Feb. 28, 2023	Nov. 30, 2022	Aug. 31, 2022	Feb. 29, 2024	Feb. 28, 2023
Balance	$ 3,393,353	$ 3,401,556	$ 3,329,943	$ 4,483,146	$ 4,563,182	$ 4,441,366	$ 3,329,943	$ 4,441,366
Other comprehensive loss	(4,696)			101,735			3,716	(3,322)
Balance	3,343,041	3,393,353	3,401,556	3,406,771	4,483,146	4,563,182	3,343,041	3,406,771
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance	(38,367)	(43,561)	(46,610)	(26,110)	(2,030)	54,413	(46,610)	54,413
Other comprehensive loss	(4,820)	5,194	3,049	(16,838)	(24,080)	(56,443)
Balance	(43,187)	(38,367)	(43,561)	(42,948)	(26,110)	(2,030)	(43,187)	(42,948)
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]
Balance	0	0	0	(95,345)	(77,702)	(75,177)	0	(75,177)
Other comprehensive loss	0	0	0	95,345	(17,643)	(2,525)
Balance	0	0	0	0	(95,345)	(77,702)	0	0
Unrealized Loss on Available for Sale Debt Securities [Member]
Balance	(38,367)	(43,561)	(46,610)	(121,455)	(79,732)	(20,764)	(46,610)	(20,764)
Other comprehensive loss	(4,820)	5,194	3,049	78,507	(41,723)	(58,968)
Balance	$ (43,187)	$ (38,367)	$ (43,561)	$ (42,948)	$ (121,455)	$ (79,732)	$ (43,187)	$ (42,948)

Amount after tax and reclassification adjustments of other comprehensive income (loss).

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481674/830-30-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481694/830-30-45-17

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-4

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481694/830-30-45-20

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-SubTopic 10
-Topic 220
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482739/220-10-55-15

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483421/250-10-45-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 23
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483421/250-10-45-23

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483421/250-10-45-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-5

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480528/815-20-65-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480528/815-20-65-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480528/815-20-65-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480528/815-20-65-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480528/815-20-65-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (i)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480528/815-20-65-6

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)(3)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483550/848-10-65-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479343/105-10-65-6

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479343/105-10-65-6

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (d)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-4

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 15
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480336/718-10-65-15

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 15
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480336/718-10-65-15

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 15
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480336/718-10-65-15

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-5

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481674/830-30-50-1

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481694/830-30-45-17

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481694/830-30-45-20

Reference 29: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-11

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 205
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480767/946-205-45-3

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-3

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481231/810-10-45-15

Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481231/810-10-45-16

Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I

Note 8 - Convertible Notes Receivable (Tables)

9 Months Ended

Feb. 29, 2024

Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]

	*February 29,*		*May 31,*
	*2024*		*2023*
HEXO Convertible Note	$	—	$	28,720
MedMen Convertible Note		32,000		74,681
Total convertible notes receivable		32,000		103,401
Deduct - current portion		—		—
Total convertible notes receivable, non current portion	$	32,000	$	103,401

Note 3 - Capital Assets (Tables)

9 Months Ended

Feb. 29, 2024

Property, Plant and Equipment [Table Text Block]

	*February 29,*			*May 31,*
	*2024*			*2023*
Land	$	45,681		$	30,635
Production facility		388,234			344,627
Equipment		253,422			185,422
Leasehold improvement		9,379			7,753
Finance lease, right-of-use assets		56,225			—
Construction in progress		10,907			8,048
	$	763,848		$	576,485
Less: accumulated amortization		(185,065	)		(146,818	)
Total	$	578,783		$	429,667

Disclosure of Long-Lived Assets Held-for-Sale [Table Text Block]

	February 29,		May 31,
	2024		2023
Land	$	1,380	$	—
Production facility		20,821		—
Equipment		6,437		—
	$	28,638	$	—

Note 2 - Inventory

9 Months Ended

Feb. 29, 2024

Inventory Disclosure [Text Block]

Note 2. Inventory

Inventory consisted of the following:

	*February 29,*		*May 31,*
	*2024*		*2023*
Beverage alcohol inventory	$	47,606	$	27,837
Plants		18,623		10,884
Dried cannabis		102,043		89,801
Cannabis trim		—		322
Cannabis derivatives		4,385		9,229
Cannabis vapes		5,250		1,173
Packaging and other inventory items		21,782		19,997
Distribution inventory		33,466		30,144
Wellness inventory		10,984		11,164
Total	$	244,139	$	200,551

Consolidated Statements of Loss and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
Net revenue	$ 188,340	$ 145,589	$ 559,060	$ 442,936
Cost of goods sold	138,944	157,288	418,059	363,139
Gross profit (loss)	49,396	(11,699)	141,001	79,797
Operating expenses:
General and administrative	39,940	38,999	123,769	117,385
Selling	9,995	6,452	24,437	25,792
Amortization	21,558	23,518	65,700	71,872
Marketing and promotion	11,191	7,354	28,934	23,137
Research and development	106	171	241	502
Change in fair value of contingent consideration	(5,983)	352	(16,790)	563
Impairments	0	934,000	0	934,000
Other than temporary change in fair value of convertible notes receivable	42,681	181,376	42,681	181,376
Litigation costs, net of recoveries	3,363	(5,230)	8,439	(1,970)
Restructuring costs	5,178	2,663	8,748	10,727
Transaction costs (income)	3,465	5,382	13,061	(3,882)
Total operating expenses	131,494	1,195,037	299,220	1,359,502
Operating loss	(82,098)	(1,206,736)	(158,219)	(1,279,705)
Interest expense, net	(8,517)	(1,040)	(26,977)	(8,560)
Non-operating income (expense), net	(17,239)	1,213	(20,820)	(50,229)
Loss before income taxes	(107,854)	(1,206,563)	(206,016)	(1,338,494)
Income tax (recovery) expense	(2,871)	(10,811)	1,013	(15,313)
Net loss	(104,983)	(1,195,752)	(207,029)	(1,323,181)
Total net income (loss) attributable to:
Stockholders of Tilray Brands, Inc.	(92,701)	(1,170,998)	(213,234)	(1,313,943)
Non-controlling interests	(12,282)	(24,754)	6,205	(9,238)
Other comprehensive gain (loss), net of tax
Foreign currency translation gain (loss)	(4,696)	6,390	3,716	(78,499)
Unrealized gain (loss) on convertible notes receivable	0	95,345	0	75,177
Total other comprehensive gain (loss), net of tax	(4,696)	101,735	3,716	(3,322)
Comprehensive loss	(109,679)	(1,094,017)	(203,313)	(1,326,503)
Total comprehensive income (loss) attributable to:
Stockholders of Tilray Brands, Inc.	(97,521)	(1,092,491)	(209,811)	(1,336,127)
Non-controlling interests	$ (12,158)	$ (1,526)	$ 6,498	$ 9,624
Weighted average number of common shares - basic (in shares)	754,439,331	615,534,670	725,346,952	597,829,714
Weighted average number of common shares - diluted (in shares)	754,439,331	615,534,670	725,346,952	597,829,714
Net loss per share - basic (in dollars per share)	$ (0.12)	$ (1.9)	$ (0.29)	$ (2.2)
Net loss per share - diluted (in dollars per share)	$ (0.12)	$ (1.9)	$ (0.29)	$ (2.2)

Note 24 - Non-operating Income (Expense) - Components of Non-operating Income (Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
Change in fair value of convertible debenture payable	$ (6,311)	$ 207	$ (12,352)	$ (20,375)
Change in fair value of warrant liability	586	5,256	(1,365)	6,841
Foreign exchange loss (gain)	(3,302)	(1,955)	1,941	(26,621)
Loss on long-term investments	33	(925)	383	(2,529)
Other non-operating (losses) gains, net	(8,245)	(1,370)	(9,427)	(7,545)
Total	$ (17,239)	$ 1,213	$ (20,820)	$ (50,229)

Note 25 - Fair Value Measurements

9 Months Ended

Feb. 29, 2024

Fair Value Disclosures [Text Block]

Note 25. Fair value measurements

Financial instruments

The Company has classified its financial instruments as described in Note 3 Significant accounting policies in our Annual Financial Statements.

The carrying values of marketable securities, accounts receivable, bank indebtedness and accounts payable and accrued liabilities approximate their fair values due to their short periods to maturity.

At February 29, 2024 and May 31, 2023 the Company had long-term debt of $3,846 and $3,280, respectively, and the principal portion of convertible debentures payable of $258,530 and $464,070, respectively, subject to fixed interest rates. The Company’s long-term debt is valued based on discounting the future cash outflows associated with the long-term debt. The discount rate is based on the incremental premium above market rates for the U.S. Department of the Treasury securities of similar duration. In each period thereafter, the incremental premium is held constant while the U.S. Department of the Treasury security is based on the then current market value to derive the discount rate.

The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of February 29, 2024 and May 31, 2023 and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:

								*February 29,*
	*Level 1*		*Level 2*		*Level 3*			*2024*
Financial assets
Cash and cash equivalents	$	146,253	$	—	$	—		$	146,253
Marketable securities		79,605		—		—			79,605
Convertible notes receivable		—		—		32,000			32,000
Equity investments measured at fair value		1,104		1,454		5,500			8,058
Financial liabilities
Warrant liability		—		—		(3,182	)		(3,182	)
Contingent consideration		—		—		(14,000	)		(14,000	)
APHA 24 Convertible debenture		—		—		(83,351	)		(83,351	)
Total recurring fair value measurements	$	226,962	$	1,454	$	(63,033	)	$	165,383

								*May 31,*
	*Level 1*		*Level 2*		*Level 3*			*2023*
Financial assets
Cash and cash equivalents	$	206,632	$	—	$	—		$	206,632
Marketable Securities		241,897		—		—			241,897
Convertible notes receivable		—		—		103,401			103,401
Equity investments measured at fair value		1,056		1,088		5,651			7,795
Financial liabilities
Warrant liability		—		—		(1,817	)		(1,817	)
Contingent consideration		—		—		(27,107	)		(27,107	)
APHA 24 Convertible debenture		—		—		(120,568	)		(120,568	)
Total recurring fair value measurements	$	449,585	$	1,088	$	(40,440	)	$	410,233

The Company’s financial assets and liabilities required to be measured on a recurring basis are its convertible notes receivable, equity investments measured at fair value, convertible debentures measured at fair value, acquisition-related contingent consideration, and warrant liability.

Convertible notes receivable and long-term investments are recorded at fair value. The estimated fair value is determined using the Black Scholes option pricing model, probability of legalization and is classified as Level 3.

Convertible debentures payable are recorded at fair value when elected or required under US GAAP. Specifically, the APHA 24 instrument's estimated fair value is determined using the Black-Scholes option pricing model and is classified as Level 3.

Certain equity investments recorded at fair value have quoted prices in active markets for identical assets and are classified as Level 1. The Company classified securities with observable inputs as Level 2 and without a quoted market price as Level 3.

The warrants associated with the warrant liability are classified as Level 3 derivatives. Consequently, the estimated fair value of the warrant liability is determined using the Black-Scholes pricing model. Until the warrants are exercised, expire, or other facts and circumstances lead the warrant liability to be reclassified to stockholders’ equity, the warrant liability (which relates to warrants to purchase shares of common stock) is marked-to-market each reporting period with the change in fair value recorded in change in fair value of warrant liability. Any significant adjustments to the unobservable inputs disclosed in the table below would have a direct impact on the fair value of the warrant liability.

The contingent consideration from the acquisition of Montauk due in December 2025, and upon the triggering event if met, and are payable in cash, was determined by discounting future expected cash outflows at a discount rate of 11%, and probability of achievement of 95%. The unobservable inputs into the future expected cash outflows result in a fair value measurement classified as Level 3. During the nine months ended February 29, 2024, a decrease in fair value of $13,493, inclusive of changes in foreign exchange, was recognized and was comprised of a decrease of fair value of $16,218 for the contingent consideration from the Sweetwater acquisition as a result of not achieving the incentive targets which was offset by an increase in fair value of $3,111 for the contingent consideration from the Montauk acquisition as a result of a higher probability of achieving the incentive targets. During the quarter end, $4,181 of contingent consideration liability from the Truss acquisition has been settled in cash for $760 (CAD $1,041)

The balances of assets and liabilities categorized within Level 3 of the fair value hierarchy measured at fair value on a recurring basis are reconciled, as follows:

													*APHA 24*
	*Convertible*			*Equity*			*Warrant*			*Contingent*			*Convertible*
	*notes receivable*			*Investments*			*Liability*			*Consideration*			*Debt*
Balance, May 31, 2023	$	103,401		$	5,651		$	(1,817	)	$	(27,107	)	$	(120,568	)
Additions/(Repayments)		—			—			—			(4,181	)		50,710
Redemption		(28,720	)		—			—			760			—
Unrealized gain (loss) on fair value		—			(151	)		(1,365	)		16,528			(13,493	)
Impairments		(42,681	)		—			—			—			—
Balance, February 29, 2024	$	32,000		$	5,500		$	(3,182	)	$	(14,000	)	$	(83,351	)

The unrealized gain (loss) on fair value for the convertible debenture, the warrant liability, contingent consideration, and debt securities classified under available-for-sale method is recognized in the consolidated statements of loss and comprehensive loss using the following inputs:

		*Significant*
	*Valuation*	*unobservable*
Financial asset / financial liability	*technique*	*input*	*Inputs*
APHA Convertible debentures	Black-Scholes	Volatility,	50%
		expected life (in years)	0.3
Warrant liability	Black-Scholes	Volatility,	50%
		expected life (in years)	1.6
Contingent consideration	Discounted cash flows	Discount rate,	11	%
		achievement	95%

Items measured at fair value on a non-recurring basis

The Company's prepaids and other current assets, long lived assets, including property and equipment, goodwill and intangible assets are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There have been no changes to the Company’s capital management approach in the period. The Company considers its cash and cash equivalents and marketable securities as capital.

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

Note 18 - Income Taxes

9 Months Ended

Feb. 29, 2024

Income Tax Disclosure [Text Block]

Note 18. Income taxes

The determination of the Company’s overall effective tax rate requires significant judgment, the use of estimates, and the interpretation and application of complex tax laws. The effective tax rate reflects the income earned and taxed in various United States federal, state, and foreign jurisdictions. Tax law changes, increases, and decreases in temporary and permanent differences between book and tax items, valuation allowances against the deferred tax assets, stock compensation, and the Company’s change in income in each jurisdiction all affect the overall effective tax rate. It is the Company’s practice to recognize interest and penalties related to uncertain tax positions in income tax expense.

The Company reported income tax (recovery) expense of $(2,871) and $1,013 for the three and nine months ended February 29, 2024, and income tax recovery of $(10,811) and $ (15,313) for the three and nine months ended February 28, 2023 The income tax benefit in the current period varies from the US statutory income tax rate and prior period primarily due to the geographical mix of earnings and losses with no tax benefit resulting from valuation allowances in certain jurisdictions.

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

Note 15 - Stockholders' Equity - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
Stock-based compensation expense	$ 8,059	$ 9,630	$ 24,517	$ 29,766
Share-Based Payment Arrangement, Option [Member]
Stock-based compensation expense		20		644
Restricted Stock Units (RSUs) [Member]
Stock-based compensation expense	$ 8,059	$ 9,610	$ 24,517	$ 29,122

Note 6 - Goodwill (Tables)

9 Months Ended

Feb. 29, 2024

Schedule of Goodwill [Table Text Block]

	*February 29,*			*May 31,*
Reporting Unit	*2024*			*2023*
Cannabis	$	2,640,669		$	2,640,669
Distribution		4,458			4,458
Beverage alcohol		120,802			120,802
Wellness		77,470			77,470
Effect of foreign exchange		8,664			7,875
Impairments		(842,431	)		(842,431	)
Total	$	2,009,632		$	2,008,843

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-2

Note 6 - Goodwill

9 Months Ended

Feb. 29, 2024

Goodwill Disclosure [Text Block]

Note 6. Goodwill

The following table shows the carrying amount of goodwill by reporting units:

	*February 29,*			*May 31,*
Reporting Unit	*2024*			*2023*
Cannabis	$	2,640,669		$	2,640,669
Distribution		4,458			4,458
Beverage alcohol		120,802			120,802
Wellness		77,470			77,470
Effect of foreign exchange		8,664			7,875
Impairments		(842,431	)		(842,431	)
Total	$	2,009,632		$	2,008,843

Note 5 - Intangible Assets (Details Textual) - USD ($)	Feb. 29, 2024	May 31, 2023
Licenses, Permits and Applications [Member]
Indefinite-Lived Intangible Assets (Excluding Goodwill)	$ 182,851	$ 181,093

Note 24 - Non-operating Income (Expense) (Tables)

9 Months Ended

Feb. 29, 2024

Schedule of Other Nonoperating Income (Expense) [Table Text Block]

	*For the three months ended*						*For the nine months ended*
	*February 29,*			*February 28,*			*February 29,*			*February 28,*
	*2024*			*2023*			*2024*			*2023*
Change in fair value of convertible debenture payable	$	(6,311	)	$	207		$	(12,352	)	$	(20,375	)
Change in fair value of warrant liability		586			5,256			(1,365	)		6,841
Foreign exchange loss (gain)		(3,302	)		(1,955	)		1,941			(26,621	)
Loss on long-term investments		33			(925	)		383			(2,529	)
Other non-operating (losses) gains, net		(8,245	)		(1,370	)		(9,427	)		(7,545	)
Total	$	(17,239	)	$	1,213		$	(20,820	)	$	(50,229	)

Note 8 - Convertible Notes Receivable

9 Months Ended

Feb. 29, 2024

Loans, Notes, Trade and Other Receivables Disclosure [Text Block]

Note 8. Convertible notes receivable

Convertible notes receivable is comprised of the following:

	*February 29,*		*May 31,*
	*2024*		*2023*
HEXO Convertible Note	$	—	$	28,720
MedMen Convertible Note		32,000		74,681
Total convertible notes receivable		32,000		103,401
Deduct - current portion		—		—
Total convertible notes receivable, non current portion	$	32,000	$	103,401

HEXO Convertible Note

On June 22, 2023, the Company completed the HEXO Acquisition as described in Note 7 (Business acquisitions). Concurrently with the closing of the HEXO Acquisition, the HEXO convertible note was converted into shares of HEXO.

MedMen Convertible Note

On August 31, 2021, the Company issued 9,817,061 shares valued at $117,804 to acquire 68% interest in Superhero Acquisition L.P. (“SH Acquisition”), which purchased a senior secured convertible note issued by MedMen (the "MedMen Convertible Note"), together with certain associated warrants to acquire Class B subordinate voting shares of MedMen, in the principal amount of $165,799. The MedMen Convertible Note bears interest at the Secured Overnight Financing Rate ("SOFR") plus 6%, with a SOFR floor of 2.5% with any accrued interest being added to the outstanding principal amount. The outstanding principal amount, together with accrued interest is to be paid on August 17, 2028, the maturity date of the MedMen Convertible Note. SH Acquisition was also granted “top-up” rights enabling it (and its limited partners) to maintain its percentage ownership (on an “as-converted” basis) in the event that MedMen issues equity securities. SH Acquisition’s ability to convert the MedMen Convertible Note and exercise the Warrants is dependent upon U.S. federal legalization of cannabis or Tilray’s waiver of such requirement as well as any additional regulatory approvals.

During the three months ended February 29, 2024, the Company recognized an other-than-temporary change in fair value, which resulted in a non-cash expense of $42,681. The MedMen Convertible Note was valued based upon the fair value of the collateral assets net of disposal costs and has been reduced to reflect recent events, including the appointment of a chief restructuring officer on January 23, 2024 and pending asset sales. In the prior year, the Company used the Black-Scholes model using the following assumptions: the risk-free rate of 3.50%; expected life of the convertible note; volatility of 70% based on comparable companies; forfeiture rate of nil; dividend yield of nil; probability of legalization between 0% and 60%; and, the exercise price of the respective conversion feature.

The Company did not derive any revenue or cash from MedMen's operations, and fully complies with all limitations imposed by applicable U.S. law and regulations in connection with its ownership of the MedMen Convertible Note. In addition, the Company did not recognize any interest income on the MedMen Convertible Note for the three and nine months ended February 29, 2024, which would have increased its value.

Note 21 - Cost of Goods Sold (Tables)

9 Months Ended

Feb. 29, 2024

Schedule of Cost of Goods Sold [Table Text Block]

	*For the three months ended*				*For the nine months ended*
	*February 29,*		*February 28,*		*February 29,*		*February 28,*
	*2024*		*2023*		*2024*		*2023*
Beverage alcohol costs	$	35,836	$	10,663	$	77,615	$	32,932
Cannabis costs		42,518		80,362		139,507		137,800
Distribution costs		51,231		57,964		172,846		165,443
Wellness costs		9,359		8,299		28,091		26,964
Total	$	138,944	$	157,288	$	418,059	$	363,139

Note 25 - Fair Value Measurements - Reconciliation of Level 3 Assets and Liabilities (Details) - Fair Value, Inputs, Level 3 [Member] $ in Thousands	9 Months Ended
	Feb. 29, 2024 USD ($)
Equity Investments [Member]
Balance	$ 5,651
Additions/(Repayments)	0
Redemption	0
Unrealized gain (loss) on fair value	(151)
Impairments	0
Balance	5,500
Warrant Liability [Member]
Balance	(1,817)
Additions/(Repayments)	0
Redemption	0
Unrealized gain (loss) on fair value	(1,365)
Impairments	0
Balance	(3,182)
Contingent Consideration [Member]
Balance	(27,107)
Additions/(Repayments)	(4,181)
Redemption	760
Unrealized gain (loss) on fair value	16,528
Impairments	0
Balance	(14,000)
Long-Term Debt [Member] \| APHA 24 [Member]
Balance	(120,568)
Additions/(Repayments)	50,710
Redemption	0
Unrealized gain (loss) on fair value	(13,493)
Impairments	0
Balance	(83,351)
Notes Receivable [Member]
Balance	103,401
Additions/(Repayments)	0
Redemption	(28,720)
Unrealized gain (loss) on fair value	0
Impairments	(42,681)
Balance	$ 32,000

Note 12 - Long-term Debt (Details Textual) - Secured Debt [Member] $ in Millions		3 Months Ended
	Aug. 31, 2023 USD ($)	Aug. 31, 2023 USD ($)
Term Loan Due In March Two Thousand Twenty Four [Member] \| Four Twenty Corporation [Member]
Repayments of Long-Term Debt		$ 100
Term Loan Due In June Two Thousand Twenty Eight [Member]
Long-Term Debt, Gross	$ 70	70
Debt Instrument, Maturity Date	Jun. 30, 2028
Term Loan Due In June Two Thousand Twenty Eight [Member] \| Delayed Draw Term Loan [Member]
Long-Term Debt, Gross	$ 20	$ 20

Note 3 - Capital Assets - Assets Held for Sale (Details) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Assets, Held for sale	$ 28,638	$ 0
Land [Member]
Assets, Held for sale	1,380	0
Production Facility [Member]
Assets, Held for sale	20,821	0
Equipment [Member]
Assets, Held for sale	$ 6,437	$ 0

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Feb. 29, 2024	Apr. 05, 2024
Document Information [Line Items]
Entity Central Index Key	0001731348
Entity Registrant Name	Tilray Brands, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--05-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Feb. 29, 2024
Document Transition Report	false
Entity File Number	001-38594
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-4310622
Entity Address, Address Line One	265 Talbot Street West
Entity Address, City or Town	Leamington
Entity Address, State or Province	ON
Entity Address, Postal Zip Code	N8H 5L4
City Area Code	844
Local Phone Number	845-7291
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	TLRY
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		774,028,558

Note 23 - Restructuring Charges

9 Months Ended

Feb. 29, 2024

Restructuring and Related Activities Disclosure [Text Block]

Note 23. Restructuring charges

In connection with the execution of our acquisition strategy and strategic transactions, the Company has incurred restructuring and exit costs associated with the integration efforts of these non-recurring transactions. The Company recognized $5,178 and $8,748 of restructuring charges for the three and nine months ended February 29, 2024, respectively, compared to $2,663 and $10,727 for prior year comparative periods. The Company approves detailed restructuring initiative plans at the executive level and recognizes these expenses in the period in which the plan has been committed to. All amounts incurred as of February 29, 2024, have been paid.

Within the Cannabis reporting unit, three restructuring plans have been initiated as follows; HEXO acquisition related charges which is expected to take place within 24 months from the acquisition date, Truss acquisition related charges which is expected to take place within 18 months from the acquisition date and the Canadian business cost reduction plan, which concluded during the last quarter. In the nine months ended February 29, 2024, the following expenses were recognized, $3,987 of employee termination benefits and other restructuring charges for the HEXO acquisition plan, $3,454 of restructuring charges related to the costs of exiting the Truss facility until the new business has resumed for the Truss acquisition plan and $475 of employee termination benefits for the Canadian business cost reduction plan.

Within the distribution reporting unit, the Company continued to execute on a cost optimization plan during the three months ended February 29, 2024. It is expected that this plan will be completed within the current fiscal year. During the nine months ended February 29, 2024, the Company recognized $832 related to employee termination benefits in connection with the execution of this plan.

For the three and nine months ended February 28, 2023, the Company recognized $2,663 and $10,727 which was comprised of $2,663 of severance costs required to right size the Company's production, $1,599 of exit costs, and $2,758 for inventory adjustments from the termination of our producer partnership in Uruguay due to a breach of the underlying contract in our International cannabis business. Additionally, amounts related to the Tilray-Aphria Arrangement Agreement for the closure of our Canadian cannabis facility in Enniskillen of $1,512 million were incurred. The Company also incurred $2,195 million of write-offs from the exit of our medical device reprocessing business in our distribution reporting segment. These exit costs were completed in the prior year quarter ended February 28, 2023, and did not have any impacts in the nine months ended February 29, 2024.

Note 26 - Segment Reporting - Geographic Capital Assets (Details) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Capital assets	$ 578,783	$ 429,667
North America [Member]
Capital assets	473,779	319,173
EMEA [Member]
Capital assets	101,271	107,131
Rest of World [Member]
Capital assets	$ 3,733	$ 3,363

Note 9 - Long Term Investments

9 Months Ended

Feb. 29, 2024

Investment [Text Block]

Note 9. Long term investments

Long term investments consisted of the following:

	*February 29,*		*May 31,*
	*2024*		*2023*
Equity investments measured at fair value	$	2,558	$	2,144
Equity investments under measurement alternative		5,500		5,651
Total	$	8,058	$	7,795

Note 7 - Business Acquisitions (Tables)

9 Months Ended

Feb. 29, 2024

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

	*Amount*
Consideration
Cash	$	28,701
Shares		6,422
Contingent consideration		10,245
Net assets acquired
Current assets
Cash and cash equivalents		1,983
Accounts receivable		1,116
Prepaids and other current assets		467
Inventory		1,570
Long-term assets
Capital assets		420
Customer relationships (15 years)		18,540
Intellectual property, trademarks & brands (15 years)		13,650
Goodwill		17,803
Total assets		55,549
Current liabilities
Accounts payable and accrued liabilities		1,580
Long-term liabilities
Deferred tax liability		4,851
Other liabilities		3,750
Total liabilities		10,181
Total net assets acquired	$	45,368

	*Amount*
Consideration
Shares	$	63,927
Settlement of convertible notes receivable		28,720
Warrants assumed		47
Estimated fair value of HEXO stock-based compensation		1,188
Net assets acquired
Current assets
Cash and cash equivalents		14,634
Restricted cash		1,656
Accounts receivable		7,855
Asset held for sale		755
Prepaids and other current assets		2,709
Inventory		25,947
Long-term assets
Prepaid expenses		8,384
Capital assets		70,634
Intellectual property, trademarks & brands (15 years)		2,680
Interest in equity investee		3,145
Total assets		138,399
Current liabilities
Accounts payable and accrued liabilities		44,517
Total liabilities		44,517
Total net assets acquired	$	93,882

	*Amount*
Consideration
Cash consideration	$	74
Investment in equity investees		3,145
Contingent consideration		4,181
Net assets acquired
Current assets
Cash and cash equivalents		6,739
Accounts receivable		1,038
Prepaids and other current assets		78
Inventory		2,573
Asset held for sale		2,960
Long-term assets
Intangible assets		296
Total assets		13,684
Current liabilities
Accounts payable and accrued liabilities		5,408
Other liabilities		876
Total liabilities		6,284
Total net assets acquired		7,400

	*Amount*
Consideration
Cash consideration	$	83,658
Net assets acquired
Current assets
Cash and cash equivalents		77
Inventory		22,493
Prepaids and other current assets		573
Long-term assets
Capital assets		62,614
Finance lease, right-of-use assets		45,496
Operating lease, right-of-use assets		7,677
Other assets		108
Total assets		139,038
Current liabilities
Accounts payable and accrued liabilities		2,206
Current portion of finance lease liabilities		1,031
Current portion of operating lease liabilities		1,408
Long - term liabilities
Finance lease liabilities		44,465
Operating lease liabilities		6,270
Total liabilities		55,380
Total net assets acquired		83,658

Note 8 - Convertible Notes Receivable (Details Textual) $ in Thousands		3 Months Ended		9 Months Ended
	Aug. 31, 2021 USD ($) shares	Feb. 29, 2024 USD ($)	Feb. 28, 2023 USD ($)	Feb. 29, 2024 USD ($)	Feb. 28, 2023 USD ($)
Other-than-temporary Fair Value Loss, Convertible Notes Receivable		$ 42,681	$ 181,376	$ 42,681	$ 181,376
MM Notes [Member]
Financing Receivable, before Allowance for Credit Loss, Total	$ 165,799
Notes Receivable, SOFR Floor	2.50%
Other-than-temporary Fair Value Loss, Convertible Notes Receivable		42,681
MM Notes [Member] \| Convertible Debt [Member]
Interest Income, Purchased Receivables		$ 0		$ 0
MM Notes [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Notes Receivable, Measurement Input	0.035
MM Notes [Member] \| Measurement Input, Price Volatility [Member]
Notes Receivable, Measurement Input	0.70
MM Notes [Member] \| Measurement Input, Forfeiture Rate [Member]
Notes Receivable, Measurement Input	0
MM Notes [Member] \| Measurement Input, Expected Dividend Rate [Member]
Notes Receivable, Measurement Input	0
MM Notes [Member] \| Measurement Input, Probability of Legalization [Member] \| Minimum [Member]
Notes Receivable, Measurement Input	0
MM Notes [Member] \| Measurement Input, Probability of Legalization [Member] \| Maximum [Member]
Notes Receivable, Measurement Input	0.60
MM Notes [Member] \| Secured Overnight Financing Rate (SOFR) [Member]
Notes Receivable, Interest Rate, Basis Spread on Variable Rate	6.00%
Superhero Acquisition LP [Member]
Noncontrolling Interest, Ownership Percentage by Parent	68.00%	68.00%		68.00%
The MM Notes and MM Warrants [Member]
Stock Issued During Period, Shares, Acquisitions (in shares) \| shares	9,817,061
Stock Issued During Period, Value, Acquisitions	$ 117,804

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023	Jun. 22, 2023	May 31, 2023
Restricted Cash, Current	$ 0		$ 0			$ 0
Real Estate, Land, Held-for-Sale	$ 28,638,000		$ 28,638,000			$ 0
Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities (in shares)	72,653,364	36,388,651	72,653,364	36,388,651
Restricted Stock Units (RSUs) [Member]
Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements (in shares)	20,652,315	16,431,876	20,652,315	16,431,876
Share-Based Payment Arrangement, Option [Member]
Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements (in shares)	5,744,302	4,660,046	5,744,302	4,660,046
Warrant [Member]
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants (in shares)	6,209,000	6,209,000	6,209,000	6,209,000
Kirkland Lake Property [Member]
Real Estate, Land, Held-for-Sale	$ 28,638		$ 28,638
Restricted Cash, Reserved for Letters of Credit and Acquisition-related Collateral [Member]
Restricted Cash, Current					$ 1,656

Note 4 - Leases

9 Months Ended

Feb. 29, 2024

Leases Disclosure [Text Block]

Note 4. Leases

The table below presents the lease-related assets and liabilities recorded on the balance sheet.

		*February 29,*		*May 31,*
	*Classification on Balance Sheet*	*2024*		*2023*
Assets
Finance lease, right-of-use assets	Capital assets	$	56,225	$	—
Operating lease, right-of-use assets	Operating lease, right-of-use assets		17,453		5,941
Total right-of-use asset		$	73,678	$	5,941
Liabilities
Current:
Current portion of finance lease liabilities	Current portion of lease liabilities	$	1,370	$	—
Current portion of operating lease liabilities	Current portion of lease liabilities		4,054		2,423
Non-current:
Finance lease liabilities	Lease liabilities		55,674		—
Operating lease liabilities	Lease liabilities		17,554		7,936
Total lease liabilities		$	78,652	$	10,359

The following table presents the future undiscounted payment associated with lease liabilities as of February 29, 2024:

	*Operating*			*Finance*
	*leases*			*leases*
2024	$	1,635		$	1,261
2025		5,715			5,043
2026		5,361			5,043
2027		4,768			5,043
Thereafter		10,161			85,336
Total minimum lease payments	$	27,640		$	101,726
Imputed interest		(6,032	)		(44,682	)
Obligations recognized	$	21,608		$	57,044

Note 13 - Convertible Debentures Payable - Net Carrying Amount of Convertible Debentures (Details) (Parentheticals)	Feb. 29, 2024	May 31, 2023	May 30, 2023	Jul. 12, 2022	Apr. 01, 2019
TLRY 27 [Member]
Rate	5.20%	5.20%	5.20%
Interest rate	5.20%	5.20%	5.20%
HT Investments MA LLC Note [Member]
Rate	4.00%	4.00%		4.00%
Interest rate	4.00%	4.00%		4.00%
APHA 24 [Member]
Rate	5.25%	5.25%			5.25%
Interest rate	5.25%	5.25%			5.25%
TLRY 23 [Member]
Rate	5.00%	5.00%
Interest rate	5.00%	5.00%

Note 20 - Net Revenue - Components of Net Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
Net revenue	$ 188,340	$ 145,589	$ 559,060	$ 442,936
Beverage Alcohol Business [Member]
Revenue	58,247	21,941	133,237	67,209
Excise taxes	(3,559)	(1,301)	(7,882)	(4,520)
Net revenue	54,688	20,640	125,355	62,689
Cannabis Segment [Member]
Revenue	85,236	61,118	276,676	203,503
Excise taxes	(21,804)	(13,569)	(75,797)	(47,486)
Net revenue	63,432	47,549	200,879	156,017
Tilray Pharma Segment [Member]
Net revenue	56,794	65,385	193,174	186,158
Wellness Business [Member]
Net revenue	$ 13,426	$ 12,015	$ 39,652	$ 38,072

Note 12 - Long-term Debt - Net Carrying Amount of Long-term Debt Instruments (Details) € in Thousands, $ in Thousands	Feb. 29, 2024 USD ($)	Feb. 29, 2024 EUR (€)	May 31, 2023 USD ($)	May 31, 2023 EUR (€)
Credit Facility Due in November 2025 [Member]
Carrying amount of long-term debt	$ 41,440		$ 45,260
Term Loan Due in July 2033 [Member]
Carrying amount of long-term debt	10,541		10,959
Term Loan Due in July 2033 Two [Member]
Carrying amount of long-term debt	12,765		13,092
Term Loan Due in August 2026 [Member]
Carrying amount of long-term debt	288		346
Mortgage Payable Due in August 2026 [Member]
Carrying amount of long-term debt	2,122		2,104
Term Loan Due in December 2023, One [Member]
Carrying amount of long-term debt	0		803
Term Loan Due in December 2023, Two [Member]
Carrying amount of long-term debt	0		755
Term Loan Due in April 2025 [Member]
Carrying amount of long-term debt	520		819
Term Loan Due in August 2028 [Member]
Carrying amount of long-term debt \| €		€ 3,326		€ 1,706
Mortgage Payable Due in October 2030 [Member]
Carrying amount of long-term debt	20,225		20,863
Term Loan Due in June 2028 [Member]
Carrying amount of long-term debt	87,750		65,000
Long-term Debt, Excluding Convertible Debentures [Member]
Carrying amount of long-term debt	178,977		161,707
Unamortized financing fees	(978)		(738)
Net carrying amount	177,999		160,969
Less principal portion included in current liabilities	(12,351)		(24,080)
Total noncurrent portion of long-term debt	$ 165,648		$ 136,889

Note 13 - Convertible Debentures Payable

9 Months Ended

Feb. 29, 2024

Convertible Debentures [Text Block]

Note 13. Convertible debentures payable

The following table sets forth the net carrying amount of the convertible debentures payable:

	*February 29,*		*May 31,*
	*2024*		*2023*
5.20% Convertible Notes ("TLRY 27")	$	126,587	$	100,476
HTI Convertible Note		—		47,834
5.25% Convertible Notes ("APHA 24")		83,351		120,568
5.00% Convertible Notes ("TLRY 23")		—		126,544
Total		209,938		395,422
Deduct - current portion		83,351		174,378
Total convertible debentures payable, non current portion	$	126,587	$	221,044

TLRY 27 Notes

	*February 29,*			*May 31,*
	*2024*			*2023*
5.20% Contractual debenture	$	172,500		$	150,000
Unamortized discount		(45,913	)		(49,524	)
Net carrying amount	$	126,587		$	100,476

The TLRY 27 convertible debentures were issued on May 30, 2023 and on June 9, 2023 by way of overallotment, in the principal amount of $172,500 (the “TLRY 27 Notes”). The TLRY 27 Notes bear interest at a rate of 5.20% per annum, payable semi-annually in arrears on June 15 and December 15 of each year, and mature on June 15, 2027, unless earlier converted. The TLRY 27 Notes are Tilray’s general unsecured obligations and rank senior in right of payment to all of Tilray’s indebtedness that is expressly subordinated in right of payment to the notes; equal in right of payment with any of Tilray’s unsecured indebtedness that is not so subordinated, including TLRY 23 and APHA 24, effectively junior in right of payment to any of Tilray’s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables but excluding intercompany obligations) of Tilray’s current or future subsidiaries. Noteholders will have the right to convert their TLRY 27 Notes into shares of Tilray’s common stock at their option, at any time, until the close of business on the second scheduled trading day immediately before June 15, 2027. The initial conversion rate is 376.6478 shares per $1,000 principal amount of TLRY 27 Notes, which represents a conversion price of approximately $2.66 per share. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events.

The TLRY 27 Notes will be redeemable, in whole and not in part, at Tilray’s option at any time on or after June 20, 2025 at a cash redemption price equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, but only if the last reported sale price of Tilray’s common stock exceeds 130% of the conversion price for a specified period of time. If certain corporate events that constitute a fundamental change occur, then, subject to a limited exception, noteholders may require Tilray to repurchase their TLRY 27 Notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date. In connection with the Company’s offering of the TLRY 27 Notes, the Company entered into a share lending agreement with an affiliate of Jefferies LLC (the “Share Borrower”), pursuant to which it lent to the Share Borrower 38,500,000 shares of the Company’s common stock (the "Borrowed Shares"). The Borrowed Shares were newly-issued shares, will be held as treasury shares until the expiration or early termination of the share lending agreement and may be used by purchasers of the TLRY 27 Notes to sell up to 38,500,000 shares of the Company’s common stock. The fair value of the share lending agreement has been recorded as part of the unamortized discount on the debenture. The Company expects that the selling stockholders will use their position created by such sales to establish their initial hedge with respect to their investments in the TLRY 27 Notes. The Company did not receive any proceeds from the sale of the Borrowed Shares.

During the three and nine months ended February 29, 2024, the Company recognized interest expense of $2,243 and $6,728 and accretion of amortized discount interest of $2,896 and $8,520. For the same periods in the prior year there was no interest or accretion of amortized discount.

HTI Convertible Note

	*February 29,*		May 31,
	*2024*		*2023*
4.00% Contractual debenture	$	—	$	50,000
Unamortized discount		—		(2,166	)
Net carrying amount	$	—	$	47,834

On July 12, 2022, the Company issued a $50,000 convertible promissory note to HTI ("HTI Convertible Note"), bearing a 4% interest rate payable on a quarterly basis and having a maturity date of September 1, 2023. On August 31, 2023, the Company settled in full the HTI Convertible Note through the issuance of shares as described in Note 15 (Stockholders' equity).

APHA 24 Notes

	*February 29,*			*May 31,*
	*2024*			*2023*
5.25% Contractual debenture	$	350,000		$	350,000
Debt settlement		(263,970	)		(213,260	)
Fair value adjustment		(2,679	)		(16,172	)
Net carrying amount	$	83,351		$	120,568

The APHA 24 convertible debentures, were entered into in April 2019, in the principal amount of $350,000, bear interest at a rate of 5.25% per annum, payable semi-annually in arrears on June 1 and December 1 of each year, and mature on June 1, 2024, unless earlier converted (the APHA 24 Notes"). The APHA 24 Notes are Tilray’s general unsecured obligations and rank senior in right of payment to all of Tilray’s indebtedness that is expressly subordinated in right of payment to the notes; equal in right of payment with any of Tilray’s unsecured indebtedness that is not so subordinated, including TLRY 27 effectively junior in right of payment to any of Tilray’s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables but excluding intercompany obligations) of Tilray’s current or future subsidiaries.

Holders of the APHA 24 Notes may convert all or any portion of such note, in multiples of $1 principal amount, at their option at any time between December 1, 2023 to the maturity date of June 1, 2024. The initial conversion which the Company may settle in cash, or common shares of Tilray, or a combination thereof, at Tilray's election, is equivalent to an initial conversion price of approximately $11.20 per common share, subject to adjustments in certain events.

The Company may redeem for cash all or part of the APHA 24, at its option, if the last reported sale price of the Company’s common shares has been at least 130% of the conversion price then in effect for at least 20 trading days during any 30 consecutive trading day period ending on and including trading day immediately preceding the date on which the Company provides notice of redemption. The redemption of the APHA 24 will be equal to 100% of the principal amount plus accrued and unpaid interest to, but excluding, the redemption date.

The Company elected the fair value option under ASC 825 Financial Instruments for the APHA 24. The APHA 24 was initially recognized at fair value on the balance sheet. All subsequent changes in fair value, excluding the impact of the change in fair value related to instrument-specific credit risk are recorded in non-operating income. The changes in fair value related to instrument-specific credit risk is recorded through other comprehensive income (loss).

During the three months ended February 29, 2024, the Company exchanged the aggregate principal of $50,710 of APHA 24 Notes for cancellation by issuing 27,228,252 shares.

The overall change in fair value of APHA 24 during the nine months ended February 29, 2024 decreased by $13,493, this was comprised of $12,352 of fair value changes and a foreign exchange loss of $1,141.

There was $86,030 principal outstanding as at February 29, 2024 compared to $136,740 as at May 31, 2023. See Note 27 (Subsequent events) for additional details.

During the three and nine months ended February 29, 2024,the Company recognized interest expense of $1,483 and $5,072, respectively and interest expense of $3,319 and $10,105, respectively for the same period in the prior year.

TLRY 23 Notes

	*February 29,*		*May 31,*
	*2024*		*2023*
5.00% Contractual debenture	$	—	$	277,856
Principal amount paid		—		(150,526	)
Unamortized discount		—		(786	)
Net carrying amount	$	—	$	126,544

The TLRY 23 Notes bore interest at a rate of 5.00% per annum, payable semi-annually in arrears on April 1 and October 1 of each year. On September 12, 2023, the Company repurchased $20,000 of its TLRY 23 Notes for cancellation by issuing 7,000,000 shares and paying $610 of cash to settle both principal and accrued interest. Upon repurchase of the TLRY 23 Notes, a portion of the settlement consideration was allocated to the equity component of the instrument and was recognized as a $1,672 reduction of additional paid-in capital in the Consolidated Statements of Changes in Equity. Additionally, this repurchase resulted in a loss of $1,062 which was recorded in other non-operating (losses) gains, net as shown in Note 24 (Non-operating income (expense)).

After cancellation, the outstanding principal balance of the TLRY 23 Notes was $107,330. On October 2, 2023, the Company repaid the remaining principal of the TLRY 23 Notes in cash upon maturity.

During the three and nine months ended February 29, 2024, the Company recognized interest expense of $nil and $2,122, respectively and interest expense of $1,748 and $6,077, respectively for the same period in the prior year.

Note 17 - Non-controlling Interests - Summary of Income Statement Information (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Feb. 29, 2024	Nov. 30, 2023	Aug. 31, 2023	Feb. 28, 2023	Nov. 30, 2022	Aug. 31, 2022	Feb. 29, 2024	Feb. 28, 2023
Net (loss) income	$ (104,983)			$ (1,195,752)			$ (207,029)	$ (1,323,181)
Other comprehensive (loss) income	(4,696)			101,735			3,716	(3,322)
Net comprehensive (loss) income	(109,679)	$ (40,980)	$ (52,654)	(1,094,017)	$ (103,875)	$ (128,611)	(203,313)	(1,326,503)
Comprehensive (loss) income attributable to NCI	$ (12,158)			$ (1,526)			6,498	9,624
Subsidiaries [Member]
Revenue							76,541	99,086
Total expenses							88,550	253,267
Net (loss) income							(12,009)	(154,181)
Other comprehensive (loss) income							303	70,431
Net comprehensive (loss) income							(11,706)	(83,750)
Comprehensive (loss) income attributable to NCI							1,162	656
Additional income attributable to NCI							5,336	8,968
Net comprehensive (loss) income attributable to NCI							6,498	9,624
Superhero Acquisition LP [Member]
Revenue							0	0
Total expenses							42,681	107,297
Net (loss) income							(42,681)	(107,297)
Other comprehensive (loss) income							0	70,778
Net comprehensive (loss) income							$ (42,681)	$ (36,519)
Non-controlling interest %	32.00%			32.00%			32.00%	32.00%
Comprehensive (loss) income attributable to NCI							$ (13,658)	$ (11,686)
Additional income attributable to NCI							0	0
Net comprehensive (loss) income attributable to NCI							(13,658)	(11,686)
CC Pharma Nordic ApS [Member]
Revenue							0	126
Total expenses							(1,078)	659
Net (loss) income							1,078	(533)
Other comprehensive (loss) income							(9)	(13)
Net comprehensive (loss) income							$ 1,069	$ (546)
Non-controlling interest %	25.00%			25.00%			25.00%	25.00%
Comprehensive (loss) income attributable to NCI							$ 267	$ (137)
Additional income attributable to NCI							0	0
Net comprehensive (loss) income attributable to NCI							267	(137)
Aphria Diamond [Member]
Revenue							76,541	98,960
Total expenses							47,541	54,285
Net (loss) income							29,000	44,675
Other comprehensive (loss) income							646	(707)
Net comprehensive (loss) income							$ 29,646	$ 43,968
Non-controlling interest %	49.00%			49.00%			49.00%	49.00%
Comprehensive (loss) income attributable to NCI							$ 14,527	$ 21,544
Additional income attributable to NCI							5,336	8,968
Net comprehensive (loss) income attributable to NCI							19,863	30,512
ColCanna S.A.S. [Member]
Revenue							0	0
Total expenses							(594)	91,026
Net (loss) income							594	(91,026)
Other comprehensive (loss) income							(334)	373
Net comprehensive (loss) income							$ 260	$ (90,653)
Non-controlling interest %	10.00%			10.00%			10.00%	10.00%
Comprehensive (loss) income attributable to NCI							$ 26	$ (9,065)
Additional income attributable to NCI							0	0
Net comprehensive (loss) income attributable to NCI							$ 26	$ (9,065)

Note 9 - Long-term Investments - Schedule of Long-term Investments (Details) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Equity investments measured at fair value	$ 2,558	$ 2,144
Equity investments under measurement alternative	5,500	5,651
Total	$ 8,058	$ 7,795

Note 19 - Commitments and Contingencies (Details Textual) $ in Thousands, $ in Millions	Mar. 05, 2024 USD ($)	Dec. 02, 2022 USD ($)	Feb. 21, 2020 CAD ($)	Feb. 29, 2024 USD ($)	May 31, 2023 USD ($)	Feb. 28, 2023 USD ($)	Feb. 28, 2023 CAD ($)
Loss Contingency, Damages Sought, Value		$ 27,500
Financing Receivable, after Allowance for Credit Loss				$ 32,000	$ 103,401
Litigation Settlement, Amount Awarded to Other Party	$ 19,950
Loss Contingency Accrual				25,153	$ 25,000
Cannfections Group Inc. [Member] \| High Park [Member]
Equity Method Investment, Ownership Percentage		50.00%
HEXO Acquisition [Member]
Loss Contingency Accrual				12,253
Craft Beverage Business Acquisition [Member]
Loss Contingency Accrual				$ 0
Tilray and High Park vs. 420 Investments Unpaid Debt Collection [Member]
Debt Instrument, Face Amount							$ 7
Tilray and High Park vs. 420 Investments Unpaid Debt Collection [Member] \| Collectability of Receivables, Face Amount [Member]
Financing Receivable, after Allowance for Credit Loss							$ 7
Tilray and High Park vs. 420 Investments Unpaid Debt Collection [Member] \| Collectability of Receivables Interest and Costs [member]
Interest Receivable						$ 2,800
Pending Litigation [Member] \| The 420 Investments Ltd. Litigation [Member] \| Damages [Member]
Loss Contingency, Damages Sought, Value			$ 110
Pending Litigation [Member] \| The 420 Investments Ltd. Litigation [Member] \| Aggravated Damages [Member]
Loss Contingency, Damages Sought, Value			$ 20

Note 22 - General and Administrative Expenses (Details Textual) - 9 months ended Feb. 29, 2024 $ in Thousands, $ in Millions	USD ($)	CAD ($)
Accounts Receivable, Credit Loss Expense (Reversal)	$ 4,440	$ 6

Note 12 - Long-term Debt

9 Months Ended

Feb. 29, 2024

Long-Term Debt [Text Block]

Note 12. Long-term debt

The following table sets forth the net carrying amount of long-term debt instruments:

	*February 29,*			*May 31,*
	*2024*			*2023*
Credit facility - C$66,000 - Canadian prime interest rate plus an applicable margin, 3-year term, with a 10-year amortization, repayable in blended monthly payments, due in November 2025	$	41,440		$	45,260
Term loan - C$25,000 - Canadian prime plus 1.00%, compounded monthly, 5-year term, with a 15-year amortization, repayable in equal monthly installments of C$181 including interest, due in July 2033		10,541			10,959
Term loan - C$25,000 - Canadian prime plus 1.00%, compounded monthly, 5-year term, with a 15-year amortization, repayable in equal monthly installments of C$196 including interest, due in July 2033		12,765			13,092
Term loan - C$1,250 - Canadian prime plus 1.50%, 5-year term, with a 10-year amortization, repayable in equal monthly installments of C$12 including interest, due in August 2026		288			346
Mortgage payable - C$3,750 - Canadian prime plus 1.50%, 5-year term, with a 20-year amortization, repayable in equal monthly installments of C$23 including interest, due in August 2026		2,122			2,104
Term loan ‐ €5,000 ‐ EURIBOR plus 2.15%, 5‐year term, repayable in quarterly installments of €250 plus interest, due in December 2023		—			803
Term loan ‐ €1,200 ‐ at 4.26%, 1‐year term, repayable in monthly installments of €100 plus interest, due in December 2023		—			755
Term loan ‐ €1,500 ‐ at 2.00%, 5‐year term, repayable in quarterly installments of €94 plus interest, due in April 2025		520			819
Term loan ‐ €3,500 ‐ at 4.59%, 5‐year term, repayable in monthly installments of €52 plus interest, due in August 2028		3,326			1,706
Mortgage payable - $22,635 - EURIBOR rate plus 1.5%, 10-year term, repayable in monthly installments of $57 including interest, due in October 2030		20,225			20,863
Term loan - $90,000 - SOFR plus an applicable margin, 5-year term, repayable in quarterly installments of $875 to $1,750 due in June 2028		87,750			65,000
Carrying amount of long-term debt		178,977			161,707
Unamortized financing fees		(978	)		(738	)
Net carrying amount		177,999			160,969
Less principal portion included in current liabilities		(12,351	)		(24,080	)
Total noncurrent portion of long-term debt	$	165,648		$	136,889

During the quarter ended August 31, 2023, ABC Group, repaid its $100,000 term loan and entered  into a new secured credit agreement, which is comprised of: (i) a $70,000 term loan facility, bearing interest at SOFR plus an applicable margin and having a maturity date of June 30, 2028 (the "ABC Group Term Loan"), and (ii) a $20,000 delayed draw term loan facility, issued on the same terms as the $70,000 term loan facility (the "ABC Group Delayed Draw Term Loan" and, together with the ABC Group Term Loan the "ABC Group Secured Credit Agreement"). The ABC Group Term Loan was fully drawn on June 30, 2023. The ABC Group Delayed Draw Term Loan was fully drawn on September 29, 2023 to fund part of the purchase price for the Craft Acquisition as described in Note 7 (Business acquisitions). Under the terms of the ABC Group Secured Credit Agreement, the Company pledged all of ABC Group and its subsidiaries' assets and the related equity interests, and Tilray Brands, Inc. provided a limited guarantee, as well as requiring the lenders approval to transfer assets to Tilray Brands, Inc.

Note 14 - Warrant Liability (Details Textual) - $ / shares	Feb. 29, 2024	May 31, 2023	May 01, 2023
Class of Warrant or Right, Outstanding (in shares)	6,209,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 5.95		$ 5.95
Percentage of Daily Cash Penalty	1.00%
Fair Value, Inputs, Level 3 [Member]
Estimated Fair Value of Warrant Liability Per Warrant (in dollars per share)	$ 0.512
Fair Value, Inputs, Level 3 [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.039
Fair Value, Inputs, Level 3 [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	0.50
Fair Value, Inputs, Level 3 [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	1.55
Fair Value, Inputs, Level 3 [Member] \| Measurement Input, Conversion Price [Member]
Warrants and Rights Outstanding, Measurement Input	1.61
Fair Value, Inputs, Level 3 [Member] \| Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input	1.73
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 1.61
Warrants to Purchase Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1	1

Consolidated Statements of Financial Position (Current Period Unaudited) (Parentheticals) - $ / shares	Feb. 29, 2024	May 31, 2023
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	1,198,000,000	1,198,000,000
Common stock, shares issued (in shares)	774,028,053	656,655,455
Common stock, shares outstanding (in shares)	774,028,053	656,655,455
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized (in shares)	10,000,000	10,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0

Note 11 - Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Trade payables	$ 90,163	$ 70,819
Accrued liabilities	70,744	48,394
Litigation accrual	25,153	25,000
Accrued payroll and employment related taxes	14,993	18,772
Income taxes payable	1,438	14,934
Accrued interest	3,202	8,102
Sales taxes payable	4,070	4,661
Total	$ 209,763	$ 190,682

Note 8 - Convertible Notes Receivable - Schedule of Convertible Notes Receivable (Details) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Total convertible notes receivable	$ 32,000	$ 103,401
Deduct - current portion	0	0
Total convertible notes receivable, non current portion	32,000	103,401
HEXO Convertible Notes Receivable [Member]
Total convertible notes receivable	0	28,720
MedMen Convertible Note [Member]
Total convertible notes receivable	$ 32,000	$ 74,681

Note 13 - Convertible Debentures Payable (Details Textual)				1 Months Ended	3 Months Ended				9 Months Ended		12 Months Ended
	Oct. 02, 2023 USD ($)	Sep. 12, 2023 USD ($) shares	May 30, 2023 USD ($) $ / shares shares	Apr. 30, 2019	Feb. 29, 2024 USD ($) shares	Nov. 30, 2023 USD ($)	Feb. 28, 2023 USD ($)	Aug. 31, 2022 USD ($)	Feb. 29, 2024 USD ($) shares	Feb. 28, 2023 USD ($)	May 31, 2023 USD ($)	Jul. 12, 2022 USD ($)	Apr. 01, 2019 USD ($) $ / shares
Accretion Expense									$ 11,463,000	$ 7,941,000
Convertible Debt, Current					$ 83,351,000				83,351,000		$ 174,378,000
Repayments of Convertible Debt									107,330,000	(0)
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature						$ 1,672,000
Other Nonoperating Gains (Losses)					(8,245,000)		$ (1,370,000)		(9,427,000)	(7,545,000)
TLRY 27 [Member]
Debt Instrument, Face Amount			$ 172,500,000		$ 172,500,000				$ 172,500,000		$ 150,000,000
Debt Instrument, Interest Rate, Stated Percentage			5.20%		5.20%				5.20%		5.20%
Debt Instrument, Convertible, Conversion Ratio			376.6478
Debt Instrument, Convertible, Multiples of Principal Amount			$ 1,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) \| $ / shares			$ 2.66
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger			130.00%
Own-share Lending Arrangement, Shares, Issued (in shares) \| shares			38,500,000
Interest Expense, Debt					$ 2,243,000				$ 6,728,000
Accretion Expense					$ 2,896,000				$ 8,520,000
HT Investments MA LLC Note [Member]
Debt Instrument, Face Amount											$ 50,000,000	$ 50,000,000
Debt Instrument, Interest Rate, Stated Percentage					4.00%				4.00%		4.00%	4.00%
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature								$ 9,055,000
APHA 24 [Member]
Debt Instrument, Face Amount					$ 350,000,000				$ 350,000,000		$ 350,000,000		$ 350,000,000
Debt Instrument, Interest Rate, Stated Percentage					5.25%				5.25%		5.25%		5.25%
Debt Instrument, Convertible, Conversion Price (in dollars per share) \| $ / shares													$ 11.2
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger				130.00%
Interest Expense, Debt					$ 1,483,000		3,319,000		$ 5,072,000	10,105,000
Debt Instrument, Convertible, Threshold Trading Days				20
Debt Instrument, Convertible, Threshold Consecutive Trading Days				30
Debt Instrument, Redemption Price, Including Interest, Percentage				100.00%
Debt Instrument, Repurchase Amount					$ 50,710,000				$ 50,710,000
Stock Issued During Period, Shares, For The Repayment of Convertible Debt (in shares) \| shares					27,228,252				27,228,252
Debt Instrument, Increase (Decrease), Net									$ (13,493,000)
Debt Instrument, Fair Value Adjustment									12,352,000
Foreign Exchange Impact					$ 1,141,000				1,141,000
Convertible Debt, Current					86,030,000				86,030,000		$ 136,740,000
Repayments of Convertible Debt					263,970,000						213,260,000
TLRY 23 [Member]
Debt Instrument, Face Amount					$ 0				$ 0		$ 277,856,000
Debt Instrument, Interest Rate, Stated Percentage					5.00%				5.00%		5.00%
Interest Expense, Debt					$ 0		$ 1,748,000		$ 2,122,000	$ 6,077,000
Debt Instrument, Repurchase Amount		$ 20,000,000
Stock Issued During Period, Shares, For The Repayment of Convertible Debt (in shares) \| shares		7,000,000							7,000,000
Repayments of Convertible Debt	$ 107,330,000	$ 610,000			$ (0)						$ 150,526,000
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature		1,672,000
Other Nonoperating Gains (Losses)		$ (1,062,000)

Note 24 - Non-operating Income (Expense)

9 Months Ended

Feb. 29, 2024

Other Nonoperating Income and Expense [Text Block]

Note 24. Non-operating income (expense)

Non-operating income (expense) is comprised of:

	*For the three months ended*						*For the nine months ended*
	*February 29,*			*February 28,*			*February 29,*			*February 28,*
	*2024*			*2023*			*2024*			*2023*
Change in fair value of convertible debenture payable	$	(6,311	)	$	207		$	(12,352	)	$	(20,375	)
Change in fair value of warrant liability		586			5,256			(1,365	)		6,841
Foreign exchange loss (gain)		(3,302	)		(1,955	)		1,941			(26,621	)
Loss on long-term investments		33			(925	)		383			(2,529	)
Other non-operating (losses) gains, net		(8,245	)		(1,370	)		(9,427	)		(7,545	)
Total	$	(17,239	)	$	1,213		$	(20,820	)	$	(50,229	)

Included in other non-operating (losses) gains, net for the three and nine months ended February 29, 2024, are losses of $(8,245) and $(9,427) which is comprised of $2,313 from the downside protection share issuance relating to the HTI note, as described in Note 15 (Stockholders' equity), $2,458 of amounts to settle outstanding notes with non-controlling interest shareholders, and $4,638 for a decrease in value of equity investee, as described in Note 19 (Commitments and contingencies), Cannfections.

Note 4 - Leases (Tables)

9 Months Ended

Feb. 29, 2024

Lessee, Operating and Finance Lease, Liabilities, to be Paid, Maturity [Table Text Block]

		*February 29,*		*May 31,*
	*Classification on Balance Sheet*	*2024*		*2023*
Assets
Finance lease, right-of-use assets	Capital assets	$	56,225	$	—
Operating lease, right-of-use assets	Operating lease, right-of-use assets		17,453		5,941
Total right-of-use asset		$	73,678	$	5,941
Liabilities
Current:
Current portion of finance lease liabilities	Current portion of lease liabilities	$	1,370	$	—
Current portion of operating lease liabilities	Current portion of lease liabilities		4,054		2,423
Non-current:
Finance lease liabilities	Lease liabilities		55,674		—
Operating lease liabilities	Lease liabilities		17,554		7,936
Total lease liabilities		$	78,652	$	10,359

	*Operating*			*Finance*
	*leases*			*leases*
2024	$	1,635		$	1,261
2025		5,715			5,043
2026		5,361			5,043
2027		4,768			5,043
Thereafter		10,161			85,336
Total minimum lease payments	$	27,640		$	101,726
Imputed interest		(6,032	)		(44,682	)
Obligations recognized	$	21,608		$	57,044

Note 14 - Warrant Liability

9 Months Ended

Feb. 29, 2024

Warrants [Text Block]

Note 14. Warrant liability

As of February 29, 2024 and May 31, 2023, there were 6,209,000 warrants outstanding, with an original exercise price of $5.95 per warrant, expiring September 17, 2025. Each warrant is exercisable for one common share of the Company.

The warrants contain anti-dilution price protection features, which adjust the exercise price of the warrants if the Company subsequently issues common stock at a price lower than the exercise price of the warrants. In the event additional warrants or convertible debt are issued with a lower and/or variable exercise price, the exercise price of the warrants will be adjusted accordingly. During the nine months ended February 29, 2024, the Company issued shares which triggered the anti-dilution price protection feature lowering the exercise price to $1.61. These warrants are classified as liabilities as they are to be settled in registered shares, and the registration statement is required to be active, unless such shares may be subject to an applicable exemption from registration requirements. The holders, at their sole discretion, may elect to affect a cashless exercise, and be issued exempt securities in accordance with Section 3(a)(9) of the 1933 Act. In the event the Company does not maintain an effective registration statement, the Company may be required to pay a daily cash penalty equal to 1% of the number of shares of common stock due to be issued multiplied by any trading price of the common stock between the exercise date and the share delivery date, as selected by the holder. Alternatively, the Company may deliver registered common stock purchased by the Company in the open market. The Company may also be required to pay cash if it does not have sufficient authorized shares to deliver to the holders upon exercise.

The Company estimated the fair value of warrants outstanding at February 29, 2024 at $0.512 per warrant using the Black Scholes pricing model (Level 3) with the following assumptions: Risk-free interest rate of 3.9%, expected volatility of 50%, expected term of 1.55 years, strike price of $1.61 and fair value of common stock of $1.73.

Expected volatility is based on both historical and implied volatility of the Company’s common stock.

Note 26 - Segment Reporting - Schedule of Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
Net revenue	$ 188,340	$ 145,589	$ 559,060	$ 442,936
Cost of goods sold	138,944	157,288	418,059	363,139
Gross Profit	49,396	(11,699)	141,001	79,797
Cannabis Segment [Member]
Net revenue	63,432	47,549	200,879	156,017
Cost of goods sold	42,518	80,362	139,507	137,800
Gross Profit	20,914	(32,813)	61,372	18,217
Revenue	85,236	61,118	276,676	203,503
Excise taxes	(21,804)	(13,569)	(75,797)	(47,486)
Cannabis Segment [Member] \| Medical Cannabis Products [Member]
Revenue	6,363	6,035	18,793	18,920
Cannabis Segment [Member] \| Adult-use Cannabis Products [Member]
Revenue	62,107	45,318	205,350	156,063
Cannabis Segment [Member] \| Wholesale Cannabis Products [Member]
Revenue	2,764	58	12,348	686
Cannabis Segment [Member] \| International Cannabis Products [Member]
Revenue	14,002	9,707	40,185	27,834
Beverage Alcohol Business [Member]
Net revenue	54,688	20,640	125,355	62,689
Cost of goods sold	35,836	10,663	77,615	32,932
Gross Profit	18,852	9,977	47,740	29,757
Revenue	58,247	21,941	133,237	67,209
Excise taxes	(3,559)	(1,301)	(7,882)	(4,520)
Tilray Pharma Segment [Member]
Net revenue	56,794	65,385	193,174	186,158
Cost of goods sold	51,231	57,964	172,846	165,443
Gross Profit	5,563	7,421	20,328	20,715
Wellness Business [Member]
Net revenue	13,426	12,015	39,652	38,072
Cost of goods sold	9,359	8,299	28,091	26,964
Gross Profit	$ 4,067	$ 3,716	$ 11,561	$ 11,108

Note 10 - Bank Indebtedness (Details Textual) € in Thousands, $ in Thousands, $ in Thousands	3 Months Ended
	Feb. 29, 2024 USD ($)	Feb. 29, 2024 CAD ($)	Feb. 29, 2024 EUR (€)
Four Twenty Corporation [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 30,000
Long-Term Line of Credit, Total	$ 7,000
Line of Credit [Member] \| Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	75.00%
Line of Credit [Member] \| Aphria Inc [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 1,000
Long-Term Line of Credit, Total		$ 0
Line of Credit [Member] \| CC Pharma GmbH [Member]
Line of Credit Facility, Maximum Borrowing Capacity \| €			€ 7,500
Long-Term Line of Credit, Total	$ 8,029		€ 7,434
Number of Debt Instruments	2	2	2
Line of Credit [Member] \| CC Pharma GmbH [Member] \| Euro Short-Term Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	2.50%
Line of Credit [Member] \| CC Pharma GmbH [Member] \| Euro Interbank Offered Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	4.00%
Operating Line of Credit One [Member] \| CC Pharma GmbH [Member]
Line of Credit Facility, Maximum Borrowing Capacity \| €			€ 7,000
Operating Line of Credit Two [Member] \| CC Pharma GmbH [Member]
Line of Credit Facility, Maximum Borrowing Capacity \| €			€ 500

Note 17 - Non-controlling Interests (Tables)

9 Months Ended

Feb. 29, 2024

Condensed Balance Sheet [Table Text Block]

	SH		*CC Pharma*			*Aphria*			*ColCanna*			*February 29,*
	*Acquisition*		*Nordic ApS*			*Diamond*			*S.A.S.*			*2024*
Current assets	$	—	$	31		$	81,541		$	191		$	81,763
Non-current assets		32,000		—			129,067			3,719			164,786
Current liabilities		—		(14	)		(129,422	)		(6,786	)		(136,222	)
Non-current liabilities		—		—			(48,218	)		(1,458	)		(49,676	)
Net assets	$	32,000	$	17		$	32,968		$	(4,334	)	$	60,651

	SH		*CC Pharma*			*Aphria*			*ColCanna*			*May 31,*
	*Acquisition*		*Nordic ApS*			*Diamond*			*S.A.S.*			*2023*
Current assets	$	—	$	114		$	127,689		$	224		$	128,027
Non-current assets		74,681		—			135,085			3,307			213,073
Current liabilities		—		(1,166	)		(142,554	)		(6,697	)		(150,417	)
Non-current liabilities		—		—			(53,197	)		(1,428	)		(54,625	)
Net assets	$	74,681	$	(1,052	)	$	67,023		$	(4,594	)	$	136,058

Condensed Income Statement [Table Text Block]

	SH			*CC Pharma*			*Aphria*			*ColCanna*			*February 29,*
	*Acquisition*			*Nordic ApS*			*Diamond*			*S.A.S.*			*2024*
Revenue	$	—		$	—		$	76,541		$	—		$	76,541
Total expenses		42,681			(1,078	)		47,541			(594	)		88,550
Net (loss) income		(42,681	)		1,078			29,000			594			(12,009	)
Other comprehensive (loss) income		—			(9	)		646			(334	)		303
Net comprehensive (loss) income	$	(42,681	)	$	1,069		$	29,646		$	260		$	(11,706	)
Non-controlling interest %		32	%		25	%		49	%		10	%	NA
Comprehensive (loss) income attributable to NCI		(13,658	)		267			14,527			26			1,162
Additional income attributable to NCI		—			—			5,336			—			5,336
Net comprehensive (loss) income attributable to NCI	$	(13,658	)	$	267		$	19,863		$	26		$	6,498

	SH			*CC Pharma*			*Aphria*			*ColCanna*			*February 28,*
	*Acquisition*			*Nordic ApS*			*Diamond*			*S.A.S.*			*2023*
Revenue	$	—		$	126		$	98,960		$	—		$	99,086
Total expenses		107,297			659			54,285			91,026			253,267
Net (loss) income		(107,297	)		(533	)		44,675			(91,026	)		(154,181	)
Other comprehensive (loss) income		70,778			(13	)		(707	)		373			70,431
Net comprehensive (loss) income	$	(36,519	)	$	(546	)	$	43,968		$	(90,653	)	$	(83,750	)
Non-controlling interest %		32	%		25	%		49	%		10	%	NA
Comprehensive (loss) income attributable to NCI		(11,686	)		(137	)		21,544			(9,065	)		656
Additional income attributable to NCI		—			—			8,968			—			8,968
Net comprehensive (loss) income attributable to NCI	$	(11,686	)	$	(137	)	$	30,512		$	(9,065	)	$	9,624

Note 10 - Bank Indebtedness

9 Months Ended

Feb. 29, 2024

Short-Term Debt [Text Block]

Note 10. Bank indebtedness

Aphria Inc., a subsidiary of the Company, has an operating line of credit in the amount of C$1,000, which bears interest at the lender’s prime rate plus 75 basis points. As of February 29, 2024, the Company has not drawn on the line of credit. The operating line of credit is secured by a security interest on certain real property located at 265 Talbot St. West, Leamington, Ontario.

CC Pharma GmbH, a subsidiary of the Company, has two operating lines of credit for €7,000 and €500 each, which bear interest at Euro Short-Term Rate ("ESTR") plus 2.50% and Euro Interbank Offered Rate ("EURIBOR") plus 4.00%, respectively. As of February 29, 2024, a total of €7,434 ($8,029) was drawn down from the available credit of €7,500. The operating line of credit for €7,000 is secured by an interest in the inventory of CC Pharma GmbH as well as the Densborn facility and underlying real property. The operating line of credit for €500 is unsecured.

American Beverage Crafts Group Inc. ("ABC Group"), formerly known as Four Twenty Corporation, a subsidiary of the Company, has a revolving credit facility of $30,000, which bears interest at SOFR plus an applicable margin. As of February 29, 2024, the Company has drawn $7,000 on the revolving line of credit. The revolving credit facility is secured by ABC Group's assets and includes a corporate guarantee by a subsidiary of the Company.

Note 4 - Leases - Schedule of Maturity (Details) $ in Thousands	Feb. 29, 2024 USD ($)
2024, operating	$ 1,635
2024, finance	1,261
2025, operating	5,715
2025, finance	5,043
2026, operating	5,361
2026, finance	5,043
2027, operating	4,768
2027, finance	5,043
Thereafter, operating	10,161
Thereafter, finance	85,336
Total minimum lease payments, operating	27,640
Total minimum lease payments	101,726
Imputed interest, operating	(6,032)
Imputed interest	(44,682)
Obligations recognized, operating	21,608
Obligations recognized	$ 57,044

Note 4 - Leases - Lease Related Assets and Liabilities (Details) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Finance lease, right-of-use assets	$ 56,225	$ 0
Operating lease, right-of-use assets	17,453	5,941
Total right-of-use asset	73,678	5,941
Total lease liabilities	78,652	10,359
Accrued Lease Obligation, Current [Member]
Current portion of finance lease liabilities	1,370	0
Current portion of operating lease liabilities	4,054	2,423
Accrued Lease Obligation, Non-current [Member]
Finance lease liabilities	55,674	0
Operating lease liabilities	$ 17,554	$ 7,936

Note 5 - Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Cost	$ 1,592,655	$ 1,576,717
Less: accumulated amortization	(246,706)	(187,088)
Less: impairments	(415,844)	(415,844)
Total	930,105	973,785
Customer Relationships and Distribution Channel [Member]
Cost	617,143	614,062
Licenses, Permits and Applications [Member]
Cost	368,649	366,793
Noncompete Agreements [Member]
Cost	12,422	12,394
Intellectual Property, Trademarks, Know How and Brands [Member]
Cost	$ 594,441	$ 583,468

Note 27 - Subsequent Events (Details Textual) - Subsequent Event [Member] - APHA 24 [Member] $ in Millions	Apr. 09, 2024 USD ($) shares
Stock Issued During Period, Value, Repurchase of Debt \| $	$ 41.9
Stock Issued During Period, Shares, Repurchase of Debt (in shares) \| shares	25,000,000

Note 20 - Net Revenue

9 Months Ended

Feb. 29, 2024

Revenue from Contract with Customer [Text Block]

Note 20. Net revenue

The Company reports its net revenue in four reporting segments: beverage alcohol, cannabis, distribution, and wellness.

Net revenue is comprised of:

	*For the three months ended*						*For the nine months ended*
	*February 29,*			*February 28,*			*February 29,*			*February 28,*
	*2024*			*2023*			*2024*			*2023*
Beverage alcohol revenue	$	58,247		$	21,941		$	133,237		$	67,209
Beverage alcohol excise taxes		(3,559	)		(1,301	)		(7,882	)		(4,520	)
Net beverage alcohol revenue		54,688			20,640			125,355			62,689
Cannabis revenue		85,236			61,118			276,676			203,503
Cannabis excise taxes		(21,804	)		(13,569	)		(75,797	)		(47,486	)
Net cannabis revenue		63,432			47,549			200,879			156,017
Distribution revenue		56,794			65,385			193,174			186,158
Wellness revenue		13,426			12,015			39,652			38,072
Total	$	188,340		$	145,589		$	559,060		$	442,936

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org//606/tableOfContent

Note 3 - Capital Assets - Schedule of Capital Assets (Details) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Capital assets, gross	$ 763,848	$ 576,485
Less: accumulated amortization	(185,065)	(146,818)
Total	578,783	429,667
Land [Member]
Capital assets, gross	45,681	30,635
Manufacturing Facility [Member]
Capital assets, gross	388,234	344,627
Equipment [Member]
Capital assets, gross	253,422	185,422
Leasehold Improvements [Member]
Capital assets, gross	9,379	7,753
Right of Use Assets [Member]
Capital assets, gross	56,225	0
Construction in Progress [Member]
Capital assets, gross	$ 10,907	$ 8,048

Consolidated Statements of Financial Position (Current Period Unaudited) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Current assets
Cash and cash equivalents	$ 146,253	$ 206,632
Marketable securities	79,605	241,897
Accounts receivable, net	89,542	86,227
Inventory	244,139	200,551
Prepaids and other current assets	43,034	37,722
Assets held for sale	28,638	0
Total current assets	631,211	773,029
Capital assets	578,783	429,667
Operating lease, right-of-use assets	17,453	5,941
Intangible assets	930,105	973,785
Goodwill	2,009,632	2,008,843
Interest in equity investees	0	4,576
Long-term investments	8,058	7,795
Convertible notes receivable	32,000	103,401
Other assets	5,614	222
Total assets	4,212,856	4,307,259
Current liabilities
Bank indebtedness	15,029	23,381
Accounts payable and accrued liabilities	209,763	190,682
Contingent consideration	0	16,218
Warrant liability	3,182	1,817
Current portion of lease liabilities	5,424	2,423
Current portion of long-term debt	12,351	24,080
Current portion of convertible debentures payable	83,351	174,378
Total current liabilities	329,100	432,979
Long - term liabilities
Contingent consideration	14,000	10,889
Lease liabilities	73,228	7,936
Long-term debt	165,648	136,889
Convertible debentures payable	126,587	221,044
Deferred tax liabilities, net	161,042	167,364
Other liabilities	210	215
Total liabilities	869,815	977,316
Commitments and contingencies (refer to Note 19)
Stockholders' equity
Common stock ($0.0001 par value; 1,198,000,000 common shares authorized; 774,028,053 and 656,655,455 common shares issued and outstanding, respectively)	77	66
Preferred shares ($0.0001 par value; 10,000,000 preferred shares authorized; nil and nil preferred shares issued and outstanding, respectively)	0	0
Additional paid-in capital	6,030,709	5,777,743
Accumulated other comprehensive loss	(43,187)	(46,610)
Accumulated Deficit	(2,628,741)	(2,415,507)
Total Tilray Brands, Inc. stockholders' equity	3,358,858	3,315,692
Non-controlling interests	(15,817)	14,251
Total stockholders' equity	3,343,041	3,329,943
Total liabilities and stockholders' equity	$ 4,212,856	$ 4,307,259

Note 19 - Commitments and Contingencies (Tables)

9 Months Ended

Feb. 29, 2024

Contractual Obligation, Fiscal Year Maturity [Table Text Block]

	*Total*		*2024*		*2025*		*2026*		*2027*		*Thereafter*
Long-term debt repayment	$	178,977	$	12,535	$	44,319	$	8,973	$	10,335	$	102,815
Convertible debentures payable		258,530		86,030		—		—		172,500		—
Material purchase obligations		49,159		21,587		27,572		—		—		—
Construction commitments		822		822		—		—		—		—
Total	$	487,488	$	120,974	$	71,891	$	8,973	$	182,835	$	102,815

Note 16 - Accumulated Other Comprehensive Income (Loss)

9 Months Ended

Feb. 29, 2024

Comprehensive Income (Loss) Note [Text Block]

Note 16. Accumulated other comprehensive income (loss)

Accumulated other comprehensive loss includes the following components:

				*Unrealized*
	*Foreign*			*loss on*
	*currency*			*convertible*
	*translation*			*notes*
	*gain (loss)*			*receivables*			*Total*
Balance May 31, 2022	$	54,413		$	(75,177	)	$	(20,764	)
Other comprehensive loss		(56,443	)		(2,525	)		(58,968	)
Balance August 31, 2022	$	(2,030	)	$	(77,702	)	$	(79,732	)
Other comprehensive loss		(24,080	)		(17,643	)		(41,723	)
Balance November 30, 2022	$	(26,110	)	$	(95,345	)	$	(121,455	)
Other comprehensive (loss) reversal		(16,838	)		95,345			78,507
Balance February 28, 2023	$	(42,948	)	$	—		$	(42,948	)

Balance May 31, 2023	$	(46,610	)	$	—		$	(46,610	)
Other comprehensive loss		3,049			—			3,049
Balance August 31, 2023	$	(43,561	)	$	—		$	(43,561	)
Other comprehensive loss		5,194			—			5,194
Balance November 30, 2023	$	(38,367	)	$	—		$	(38,367	)
Other comprehensive loss		(4,820	)		—			(4,820	)
Balance February 29, 2024	$	(43,187	)	$	—		$	(43,187	)

Note 12 - Long-term Debt (Tables)

9 Months Ended

Feb. 29, 2024

Schedule of Long-Term Debt Instruments [Table Text Block]

	*February 29,*			*May 31,*
	*2024*			*2023*
Credit facility - C$66,000 - Canadian prime interest rate plus an applicable margin, 3-year term, with a 10-year amortization, repayable in blended monthly payments, due in November 2025	$	41,440		$	45,260
Term loan - C$25,000 - Canadian prime plus 1.00%, compounded monthly, 5-year term, with a 15-year amortization, repayable in equal monthly installments of C$181 including interest, due in July 2033		10,541			10,959
Term loan - C$25,000 - Canadian prime plus 1.00%, compounded monthly, 5-year term, with a 15-year amortization, repayable in equal monthly installments of C$196 including interest, due in July 2033		12,765			13,092
Term loan - C$1,250 - Canadian prime plus 1.50%, 5-year term, with a 10-year amortization, repayable in equal monthly installments of C$12 including interest, due in August 2026		288			346
Mortgage payable - C$3,750 - Canadian prime plus 1.50%, 5-year term, with a 20-year amortization, repayable in equal monthly installments of C$23 including interest, due in August 2026		2,122			2,104
Term loan ‐ €5,000 ‐ EURIBOR plus 2.15%, 5‐year term, repayable in quarterly installments of €250 plus interest, due in December 2023		—			803
Term loan ‐ €1,200 ‐ at 4.26%, 1‐year term, repayable in monthly installments of €100 plus interest, due in December 2023		—			755
Term loan ‐ €1,500 ‐ at 2.00%, 5‐year term, repayable in quarterly installments of €94 plus interest, due in April 2025		520			819
Term loan ‐ €3,500 ‐ at 4.59%, 5‐year term, repayable in monthly installments of €52 plus interest, due in August 2028		3,326			1,706
Mortgage payable - $22,635 - EURIBOR rate plus 1.5%, 10-year term, repayable in monthly installments of $57 including interest, due in October 2030		20,225			20,863
Term loan - $90,000 - SOFR plus an applicable margin, 5-year term, repayable in quarterly installments of $875 to $1,750 due in June 2028		87,750			65,000
Carrying amount of long-term debt		178,977			161,707
Unamortized financing fees		(978	)		(738	)
Net carrying amount		177,999			160,969
Less principal portion included in current liabilities		(12,351	)		(24,080	)
Total noncurrent portion of long-term debt	$	165,648		$	136,889

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482949/835-30-55-8

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480848/942-470-50-3

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-8

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-6

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-7